<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16499977</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Changes in [(3)H]-glutamate uptake into platelets from patients with bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>343-7</MedlinePgn></Pagination><Abstract><AbstractText>Glutamate is the most abundant excitatory neurotransmitter in the mammalian brain, and it is increasingly being implicated in the pathophysiology of mental illness. In fact, changes in glutamate neurotransmission seem to be involved in the etiology of schizophrenia, major depression and bipolar disorders. Furthermore, the alterations in platelet sensitivity in major depression are distinct from those of bipolar disorders. The aim of the present investigation was to determine whether patients with bipolar disorders exhibited differences in [(3)H]-glutamate uptake of platelets. [(3)H]-Glutamate uptake of platelets from controls (n=14), patients with bipolar disorders under lithium treatment (600-1800 mg/day for 6 months) (n=7) and patients with bipolar disorders with psychotic features (n=8) were carried out. Analysis of blood platelets from the three groups of subjects revealed significant differences in [(3)H]-glutamate uptake between the control and psychotic patients. The specific glutamate uptake for the control and psychotic groups was 20.5+/-8.4 and 37.5+/-18.1 pmol glutamate/mg protein/10 min, respectively (mean+/-SD). These results indicate that peripheral glutamate metabolism of platelets is modified in bipolar disorders and that more detailed studies must be carried out to determine whether these peripheral modifications correlate with central modifications in humans and in animal models of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>do Nascimento</LastName><ForeName>Carlos A M</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Departamento de Química, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Cristina W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Borges</LastName><ForeName>Vanessa C</ForeName><Initials>VC</Initials></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>João B T</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16499977</ArticleId><ArticleId IdType="pii">S0165-1781(05)00275-1</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2005.08.023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5561067</PMID><DateCompleted><Year>1971</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>1971</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Observations on transformations of manic phases in long-term therapy with lithium].</ArticleTitle><Pagination><MedlinePgn>356-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krauss</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lauter</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Beobachtungen zum Gestaltwandel manischer Phasen unter einer Lithiumdauerbehandlung.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1971</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1971</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1971</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5561067</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6039047</PMID><DateCompleted><Year>1967</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-656X</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>4</Issue><PubDate><Year>1967</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta paediatrica Scandinavica</Title><ISOAbbreviation>Acta Paediatr Scand</ISOAbbreviation></Journal><ArticleTitle>Suicidal attempts made by psychotic children and adolescents.</ArticleTitle><Pagination><MedlinePgn>349-56</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>U</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Acta Paediatr Scand</MedlineTA><NlmUniqueID>0000211</NlmUniqueID><ISSNLinking>0001-656X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012561" MajorTopicYN="N">Schizophrenia, Childhood</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012723" MajorTopicYN="N">Sex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1967</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1967</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1967</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6039047</ArticleId><ArticleId IdType="doi">10.1111/j.1651-2227.1967.tb15392.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3167408</PMID><DateCompleted><Year>1988</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>152</Volume><PubDate><Year>1988</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Electroconvulsive therapy in parkinsonism with affective disorder.</ArticleTitle><Pagination><MedlinePgn>55-8</MedlinePgn></Pagination><Abstract><AbstractText>The authors report a patient whose Parkinson's disease and mania both responded well to electroconvulsive therapy (ECT) after failing to respond to chemotherapy. The authors review the literature and suggest that ECT is a safe and effective treatment for affective syndromes associated with Parkinsonism. The presence of dementia in these patients appears to be an indicator of poor prognosis. This paper is believed to be the first report of successful use of ECT in mania occurring together with Parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Atre-Vaidya</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Studies, University of Health Science, Chicago Medical School, Illinois 60064.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jampala</LastName><ForeName>V C</ForeName><Initials>VC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3167408</ArticleId><ArticleId IdType="pii">S0007125000137651</ArticleId><ArticleId IdType="doi">10.1192/bjp.152.1.55</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7102229</PMID><DateCompleted><Year>1982</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-7604</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>1982</Year><Month>May</Month></PubDate></JournalIssue><Title>Activitas nervosa superior</Title><ISOAbbreviation>Act Nerv Super (Praha)</ISOAbbreviation></Journal><ArticleTitle>[Combined chlorimipramine and maprotiline therapy in therapy-resistant depressions].</ArticleTitle><Pagination><MedlinePgn>88-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soucek</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Die Kombinierte Therapie mit Chlorimipramin und Maprotilin bei Therapieresistenten Depressionen.</VernacularTitle></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Act Nerv Super (Praha)</MedlineTA><NlmUniqueID>0400662</NlmUniqueID><ISSNLinking>0001-7604</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>2U1W68TROF</RegistryNumber><NameOfSubstance UI="D008376">Maprotiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>NUV44L116D</RegistryNumber><NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000873" MajorTopicYN="N">Anthracenes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002997" MajorTopicYN="N">Clomipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008376" MajorTopicYN="N">Maprotiline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7102229</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29245093</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>228</Volume><PubDate><Year>2018</Year><Month>03</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Neurocognitive functioning in first-episode Bipolar Disorder: Relationship with functional status.</ArticleTitle><Pagination><MedlinePgn>97-100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(17)31560-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2017.12.015</ELocationID><Abstract><AbstractText Label="BACKGROUND">The aim of this study was to assess if an association between neurocognitive deficits and psychosocial functioning exists in first-episode BD patients.</AbstractText><AbstractText Label="METHODS">Twenty-five euthymic first-episode BD patients and thirty-seven healthy controls were recruited. History of suicide attempts, psychiatric comorbidities, pharmacological exposure, and previous depressive episodes were investigated. Performances on neurocognitive domains (verbal memory, attention, processing speed, and executive functions) as well as a measure of psychosocial functioning were used as outcomes.</AbstractText><AbstractText Label="RESULTS">First-episode BD patients showed medium-to-large size deficits on measures of attention, processing speed, and executive functions. A significant association between verbal memory and psychosocial functioning at the moment of BD diagnosis was detected (beta coefficient -3.9, IC 95% -6.7 to -1.2, p &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">A relationship between cognitive performance at the moment of BD diagnosis and psychosocial functioning was detected. Possible therapeutic implications of this finding are discussed.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szmulewicz</LastName><ForeName>Alejandro G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; Pharmacology Department, University of Buenos Aires School of Medicine, Buenos Aires, Argentina. Electronic address: alejandroszm@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valerio</LastName><ForeName>Marina P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>National Council of Scientific and Technical Research (CONICET), Argentina; Psychiatric Emergencies Hospital Torcuato de Alvear, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomastro</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Psychiatric Emergencies Hospital Torcuato de Alvear, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>José M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Psychiatric Department, Medical Education and Clinical Research Center Norberto Quirno, CEMIC, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiappe</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Psychiatric Emergencies Hospital Torcuato de Alvear, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), Argentina; Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igoa</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; Psychiatric Emergencies Hospital Torcuato de Alvear, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29245093</ArticleId><ArticleId IdType="pii">S0165-0327(17)31560-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2017.12.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17107229</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosocial strategies to improve concordance and adherence in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>e04</MedlinePgn></Pagination><Abstract><AbstractText>Half of patients with bipolar disorder may exhibit poor medication compliance, and relapse often occurs even when patients take their medication as prescribed. Psychosocial strategies can help patients to recognize the need for treatment and, therefore, improve medication adherence. Another benefit of psychosocial strategies is that they aid patients in controlling their moods. Cognitive-behavioral therapy teaches patients to modify dysfunctional thinking and behavior. Treatment contracting allows patients to develop a plan for identifying and coping with symptoms before they become severe. Daily mood charting assists patients in quickly identifying and intervening when changes occur. Creating and following a weekly activity schedule ensures that patients will participate in enough positive activities and avoid destructive activities. Using a variety of psychosocial strategies, patients can train themselves and a support team to effectively deal with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reilly-Harrington</LastName><ForeName>Noreen</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="Y">Patient Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026684" MajorTopicYN="N">Personal Autonomy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17107229</ArticleId><ArticleId IdType="doi">10.4088/jcp.0706e04</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3988719</PMID><DateCompleted><Year>1985</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>1985</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dexamethasone suppression test results in delusional versus nondelusional depression: preliminary evidence of distinct clinical entities.</ArticleTitle><Pagination><MedlinePgn>188-90</MedlinePgn></Pagination><Abstract><AbstractText>Two patients with major affective disorder--one unipolar and one bipolar--exhibited normal DSTs while psychotically depressed (mood congruent delusions), yet exhibited nonsuppression on the DST in the course of subsequent separate nonpsychotic depressive episodes. If valid, these results may provide further evidence for considering psychotic and nonpsychotic depression as clinically distinct entities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Remick</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3988719</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22876738</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-1788</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of psychiatry in clinical practice</Title><ISOAbbreviation>Int J Psychiatry Clin Pract</ISOAbbreviation></Journal><ArticleTitle>In Iranian female and male adolescents, romantic love is related to hypomania and low depressive symptoms, but also to higher state anxiety.</ArticleTitle><Pagination><MedlinePgn>98-109</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/13651501.2012.697564</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Experiencing romantic love is important in individual development. Little is known about romantic love among adolescents in non-Western countries. The aim of the present study was to explore romantic love among Iranian male and female adolescents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 201 adolescents (mean age: 17.73 years) took part in the study; of these, 81 indicated they were experiencing romantic love at the time of survey, and 120 indicated they were not in love. Participants answered questionnaires related to affective states (hypomania, depressive symptoms, state and trait anxiety) and exercise, and completed a sleep log for seven consecutive nights.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to controls, participants in love displayed favourable hypomania scores, fewer depressive symptoms and increased concentration during the day. However, participants in love also had higher state anxiety scores. Moreover, hypomanic-like stages increased with duration of relationship in female, but not in male participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pattern of results suggests a favourable association between being currently in love and emotional and cognitive processes. Sleep, however, seemed unrelated to this specific state.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajoghli</LastName><ForeName>Hafez</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Psychiatry &amp; Psychology Research Center (PPRC), Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshaghani</LastName><ForeName>Narges</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Mohammad-Reza</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Holsboer-Trachsler</LastName><ForeName>Edith</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Psychiatry Clin Pract</MedlineTA><NlmUniqueID>9709509</NlmUniqueID><ISSNLinking>1365-1501</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="N">Adolescent Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008149" MajorTopicYN="Y">Love</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22876738</ArticleId><ArticleId IdType="doi">10.3109/13651501.2012.697564</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12656935</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Valproate, bipolar disorder and polycystic ovarian syndrome.</ArticleTitle><Pagination><MedlinePgn>28-35</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persons with bipolar disorder are often overweight and cluster risk factors for cardiovascular disease. Some antibipolar agents adversely impact upon weight and the lipid milieu. Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS). This adverse event has not been systematically studied in bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Thirty-eight female subjects, aged 18-50 years, meeting DSM-IV criteria for bipolar I or II disorder, in any phase of illness were evaluated. Eighteen females received valproate (sodium valproate and valproic acid) and 20 females received lithium. Patients completed questions regarding their menstrual, reproductive and medical histories. During the follicular phase they were assessed for weight, body mass index (BMI kg/m2), and changes in the reproductive endocrine milieu that included morning estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex-hormone binding globulin (SHBG), androstenedione, dehydroepiandrosterone-sulfate (DHEAS), testosterone, free testosterone, prolactin and thyroid-stimulating hormone (TSH). The blood was also analyzed for fasting metabolic parameters which included total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), insulin, glycosylated hemoglobin (HbA1C), insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding-protein 1 (IGFBP-1), fasting blood glucose and morning leptin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine (50%) of the valproate-treated females had menstrual abnormalities versus three (15%) of the lithium-treated females (p &lt; 0.05). Valproate-treated females had significantly higher levels of follicular phase androgen concentrations than lithium-treated females (p &lt; 0.05). Nine (50%) of females who were overweight (BMI &gt; or = 25 kg/m2) and with a history of menstrual irregularities also exhibited laboratory evidence of hyperandrogenism (p &lt; 0.05). Persons receiving valproate exhibited significant increases in fasting biochemical parameters suggestive of an adverse metabolic syndrome (p &lt; 0.05). Leptin levels were significantly elevated in the valproate-treated females (p &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this pilot, open-label cross-sectional study, valproate-treated females exhibited higher rates of menstrual abnormalities and biochemical evidence of both hyperandrogenism and adverse metabolic parameters when compared with lithium-treated females. These preliminary data suggest that valproate may, in some predisposed females, adversely impact upon the reproductive endocrine milieu and result in aspects of the metabolic syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. mcintyr@uhnres.utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Janaki</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Sidney H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011085" MajorTopicYN="N">Polycystic Ovary Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12656935</ArticleId><ArticleId IdType="pii">009</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2003.00009.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2354225</PMID><DateCompleted><Year>1990</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>1990</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment and cerebral structure by MRI in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1188-96</MedlinePgn></Pagination><Abstract><AbstractText>The distinction between bipolar disorder and schizophrenia customarily follows examination of the clinical symptomatology and course of illness. The presence of cognitive impairment has been held to be uncommon in bipolar disorder and more likely in schizophrenia. This study explored neuropsychological function in 30 ambulatory outpatients with a DSM-III-R diagnosis of bipolar affective disorder (all of whom had been psychotic during manic episodes), comparing their performance with that of controls. These bipolar patients proved to have significant levels of diffusely represented cognitive impairment when compared with controls. Further, the degree of impairment was significantly correlated with reduction in midsagittal areas of brain structures measured on magnetic resonance imaging scans. The implications of these findings in relation to bipolar disorder are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coffman</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ohio State University College of Medicine, Columbus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornstein</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Schwarzkopf</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2354225</ArticleId><ArticleId IdType="pii">0006-3223(90)90416-Y</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(90)90416-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19538682</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>11 Suppl 2</Volume><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>A critical appraisal of lithium's efficacy and effectiveness: the last 60 years.</ArticleTitle><Pagination><MedlinePgn>10-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2009.00707.x</ELocationID><Abstract><AbstractText>The history that depicts the evaluation of lithium's efficacy presents an interesting contrast: on the one hand, conviction that, of all psychotropic drugs, lithium has the best demonstrated efficacy; on the other hand, repeated attempts to question it. Those contesting lithium's stabilizing abilities have argued from several angles, for example that the proof was methodologically incorrect or insufficient, that the number of responders is small, or that the response is poor in practice and does not last. But there is a good explanation for this paradox. While the early challenges to lithium's value in recurrent mood disorders reflected mainly that psychiatry had not yet developed a methodology suitable for testing long-term efficacy, more recent questioning has resulted mostly from retesting its efficacy and effectiveness in a substantially broadened bipolar spectrum, outside the classical diagnosis. Lithium, however, continues to stabilize very well the patients suffering from typical bipolar disorder--the condition for which its efficacy was originally demonstrated. More recently, lithium has also proven to dramatically reduce suicidal behavior and mortality and to augment markedly the efficacy of antidepressants in unresponsive patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grof</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mood Disorders Center of Ottawa, Ottawa. paul_grof@mdco.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller-Oerlinghausen</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2010 Jun;12(4):455-6; author reply 457-8</RefSource><PMID Version="1">20636646</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>93</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19538682</ArticleId><ArticleId IdType="pii">BDI707</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00707.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15049773</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Studying personality characteristics in bipolar depressed subjects: how comparator group selection can dictate results.</ArticleTitle><Pagination><MedlinePgn>376-82</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the extent to which identification of any distinct personality characteristics in bipolar subjects are influenced by selection of the comparison diagnostic group.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Scores were compared on several general measures of personality style and, additionally, the prevalence of disordered personality functioning was examined in a sample of 198 non-psychotic depressed subjects, 39 with bipolar depression and 159 with unipolar depression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When the bipolar subjects were separately compared with unipolar subjects, and to sub-sets of those with clinically and DSM-IV defined melancholic and non-melancholic depression, quite differing results were suggested. In essence, clinically-defined melancholic subjects had the least personality psychopathology in comparison with the non-melancholic and bipolar subjects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Whether subjects with bipolar disorder have any distinct personality characteristics or over-represented co-morbid personality disorders remains quite unclear when reference is made to the literature. We suggest that inconsistencies across studies may reflect choice and representation of depressive sub-types within the unipolar comparator group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, and Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital, Randwick, New South Wales, Australia. g.parker@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15049773</ArticleId><ArticleId IdType="doi">10.1046/j.1600-0447.2003.00254.x</ArticleId><ArticleId IdType="pii">ACP254</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8375847</PMID><DateCompleted><Year>1993</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1597</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>8</Issue><PubDate><Year>1993</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Hospital &amp; community psychiatry</Title><ISOAbbreviation>Hosp Community Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A patient's false claim of therapist sexual misconduct.</ArticleTitle><Pagination><MedlinePgn>793-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>B D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Massachusetts Mental Health Center, Boston 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutheil</LastName><ForeName>T G</ForeName><Initials>TG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hosp Community Psychiatry</MedlineTA><NlmUniqueID>0040250</NlmUniqueID><ISSNLinking>0022-1597</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000786" MajorTopicYN="N">Anger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008192" MajorTopicYN="Y">Deception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008318" MajorTopicYN="N">Malpractice</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012742" MajorTopicYN="N">Sex Offenses</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8375847</ArticleId><ArticleId IdType="doi">10.1176/ps.44.8.793</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6480573</PMID><DateCompleted><Year>1984</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>10</Issue><PubDate><Year>1984</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium in a patient with renal failure on hemodialysis.</ArticleTitle><Pagination><MedlinePgn>444</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lippman</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Manshadi</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Gultekin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6480573</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10982202</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment.</ArticleTitle><Pagination><MedlinePgn>585-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The rare cases of patients with 48-hour ultrarapid cycling allow close investigation of mood cycles in affective disorders, because rhythmic changes in psychopathologic state and biological parameters happen very precisely.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A 67-year-old white man who had experienced bipolar 48-hour ultrarapid cycling (DSM-IV 296.80) for several years was studied without any medication and then again studied 4 weeks later during treatment with valproate (1800 mg/day).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Objective and self ratings revealed pronounced manic states 1 day and depressed states the following day, which were found to be accompanied by rhythmic fluctuations in behavior and electroencephalographic parameters, blood cortisol and growth hormone levels (both elevated on depressive days), and urinary metanephrine (dopamine metabolite) and norepinephrine levels (both elevated on manic days). Using single photon emission computed tomography, regional blood flow in the left thalamus was lower than in the right thalamus on the manic day, while symmetric perfusion of the thalamus was found on the depressive day. Under valproate treatment, the patient remitted completely, and significant rhythmic changes in most of the biological parameters were no longer detectable.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The biological findings in this patient with bipolar 48-hour ultrarapid cycling, which correspond to those in other types of affective disorders, suggest that disturbances in the diencephalon-pituitary axis may be especially correlated to pathologic changes of mood.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilians-University Munich, Germany. juckel@nk-i.med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegerl</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Mavrogiorgou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gallinat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mager</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tigges</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dresel</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schröter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stotz</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Meller</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Greil</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Möller</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12629-01-5</RegistryNumber><NameOfSubstance UI="D019382">Human Growth Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019382" MajorTopicYN="N">Human Growth Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="Y">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10982202</ArticleId><ArticleId IdType="doi">10.4088/jcp.v61n0808</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24359146</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2013</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Preceding diagnoses to young adult bipolar disorder and schizophrenia in a nationwide study.</ArticleTitle><Pagination><MedlinePgn>343</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-13-343</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this comparative study was to investigate the type and frequency of diagnoses preceding adult bipolar disorder (BD) and schizophrenia (SZ).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A follow-back study of all preceding diagnoses in all patients aged 21-34 years with a primary, first time diagnosis of BD (N = 784) or SZ (N = 1667) in 2008 to 2010. Data were taken from the Danish Psychiatric Central Research Register (DPCRR) including ICD-10 and ICD-8 diagnoses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The numbers of patients with any preceding diagnoses amounted to 69.3% in BD and 76.6% in SZ with affective disorders (excluding BD) being the most frequent preceding diagnosis (46.6 vs. 28.0%), followed by psychoses (PSY) other than SZ (14.2 vs. 41.5%, p &lt; .001), and substance use disorders (SUD) (16.1 vs. 26.9%, p &lt; .001). Reactions to severe stress were equally frequent in both samples (26.3 vs. 26.6%) as were personality disorders (21.8 vs. 22.4%) and ADHD (4.2 vs. 3.5%), whereas rates of conduct disorders (1.7 vs. 3.1%) were rather low in both samples. Very few of the preceding diagnoses had their onset in childhood and adolescence. Overall patients with SZ had a minor but statistically significant earlier onset of any psychiatric disorder compared to BD (mean age: 23.3 vs. 22.5, p &lt; .001). Regression analyses indicated that BD was associated with an increased risk of having experienced preceding affective disorders and ADHD, while SZ was associated with an increased risk of preceding substance use disorders, psychosis, anxiety disorders, and personality disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Specific developmental trajectories of preceding disorders were delineated for BD and SZ with affective disorders being more specific for BD and both SUD and PSY more specific to SZ. There are different patterns of vulnerability in terms of preceding diagnosis in young adults with BD and SZ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Søren Martin</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Aalborg Psychiatric Hospital, Aalborg University Hospital, Mølleparkvej 10, DK 9000 Aalborg, Denmark. somaa@rn.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randers</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Christina Mohr</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Bisgaard</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Steinhausen</LastName><ForeName>Hans-Christoph</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24359146</ArticleId><ArticleId IdType="pii">1471-244X-13-343</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-13-343</ArticleId><ArticleId IdType="pmc">PMC3898215</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry. 1991 May;54(2):116-32</Citation><ArticleIdList><ArticleId IdType="pubmed">1852846</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Mar;126(1-3):270-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20674280</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Nov;168(11):1186-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21676994</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Mar 1;48(1):69-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11278155</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Dec;169(12):1256-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23212057</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1998 Oct;37(10):1091-6; discussion 1096-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9785721</ArticleId></ArticleIdList></Reference><Reference><Citation>F1000 Med Rep. 2013;5:2</Citation><ArticleIdList><ArticleId IdType="pubmed">23361397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):143-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19560827</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Public Health. 2011 Jul;39(7 Suppl):54-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21775352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Apr;99(1-3):51-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17045657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jul;37(4):811-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19959704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 2010 Feb;40(2):139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19728067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jul;149(1-3):430-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23267727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):325-46, viii-ix</Citation><ArticleIdList><ArticleId IdType="pubmed">18295149</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Oct;157(10):1679-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11007724</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 2007 Sep;16(6):362-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17401612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2004 Jul;111(7):891-902</Citation><ArticleIdList><ArticleId IdType="pubmed">15206005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nord J Psychiatry. 2005;59(3):209-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16195122</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Apr;125(4):260-1</Citation><ArticleIdList><ArticleId IdType="pubmed">22404205</ArticleId></ArticleIdList></Reference><Reference><Citation>Twin Res Hum Genet. 2005 Oct;8(5):459-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16212835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1999 Jan;40(1):57-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10102726</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Dec;169(12):1247-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23212056</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2014 May;29(4):259-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24016863</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Jan;186:18-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15630119</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Oct 15;78(2-3):323-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15996855</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Mar;198(3):173-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21357874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Oct;150(1):205-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23899998</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Jun 30;188(1):29-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21056477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1996 Dec;53(12):1129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">8956679</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jul;60(7):709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12860775</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2000;26(2):411-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10885640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Oct;95(1-3):103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16793142</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Apr;163(4):716-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16585449</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2014 May;8(2):104-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24224849</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 1998 Dec;13(8):392-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19698654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18386406</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Growing evidence to support early intervention in early onset bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>92</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parsonage</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hinds</LastName><ForeName>Meredith</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Aust N Z J Psychiatry. 2007 Aug;41(8):633-6</RefSource><PMID Version="1">17620159</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18386406</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14601035</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4868</ISSN><JournalIssue CitedMedium="Print"><Volume>123C</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part C, Seminars in medical genetics</Title><ISOAbbreviation>Am J Med Genet C Semin Med Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic linkage and association studies in bipolar affective disorder: a time for optimism.</ArticleTitle><Pagination><MedlinePgn>36-47</MedlinePgn></Pagination><Abstract><AbstractText>Genetic research on complex diseases is beginning to bear fruit, with the successful identification of candidate susceptibility genes in diabetes, asthma, and other illnesses. Similar success is on the horizon for bipolar affective disorder (BPAD), but significant challenges remain. In this review, we outline the basic concepts of linkage and association mapping for complex phenotypes. We point out important caveats inherent in both approaches, and review guidelines on the interpretation of linkage statistics and significance thresholds. We then apply these concepts to an evaluation of the present status of genetic linkage and association studies in BPAD. The challenges posed by locus heterogeneity, phenotype definition, and sample size requirements are given a detailed treatment. Despite these challenges, we argue that the way ahead remains firmly rooted in linkage studies, complemented by association studies in linked regions. This is the only truly genome-wide approach currently available; it has succeeded in other complex phenotypes, and it is the surest strategy for mapping susceptibility genes in BPAD. Once these genes are identified, genetic mapping methods will yield to the other methods of 21st-century molecular biology as we begin to elucidate the pathophysiology of BPAD.</AbstractText><CopyrightInformation>Copyright 2003 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany. schulze@zi-mannheim.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Francis J</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet C Semin Med Genet</MedlineTA><NlmUniqueID>101235745</NlmUniqueID><ISSNLinking>1552-4868</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008126" MajorTopicYN="N">Lod Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016011" MajorTopicYN="N">Normal Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>114</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14601035</ArticleId><ArticleId IdType="doi">10.1002/ajmg.c.20012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18316683</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2009</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Incidence of hospitalization for postpartum psychotic and bipolar episodes.</ArticleTitle><Pagination><MedlinePgn>356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archpsyc.65.3.356-a</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Heron</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Blackmore</LastName><ForeName>Emma Robertson</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Arch Gen Psychiatry. 2007 Jan;64(1):42-8</RefSource><PMID Version="1">17199053</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2009 Mar;66(3):332</RefSource><PMID Version="1">19255383</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18316683</ArticleId><ArticleId IdType="pii">65/3/356</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.65.3.356-a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33710284</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>03</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Neuromodulation for Bipolar Disorder-The Case for Biomarker-Driven Treatment Development.</ArticleTitle><Pagination><MedlinePgn>e211055</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.1055</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Camprodon</LastName><ForeName>Joan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Netw Open. 2021 Mar 1;4(3):e210963</RefSource><PMID Version="1">33710288</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33710284</ArticleId><ArticleId IdType="pii">2777418</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.1055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11566158</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania.</ArticleTitle><Pagination><MedlinePgn>418-24</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Deficits in sensorimotor gating as assessed by prepulse inhibition (PPI) and habituation of the human startle response have been noted in schizophrenia and other patients with known dysfunction in the brain substrates that regulate PPI. During acute mania, bipolar disorder (BD) and schizophrenia patients present with symptoms that are similar. To determine if these clinical similarities extend to neurophysiologic domains, PPI and startle habituation were assessed in BD patients with acute psychotic mania and compared with a sample of acutely psychotic schizophrenia patients and a normal comparison group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifteen BD patients, 16 schizophrenia patients, and 17 control subjects were assessed on PPI and startle habituation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The BD patients had significantly lower PPI than did the control subjects in two of the three PPI conditions (60- and 120-msec interstimulus intervals) as well as less startle habituation. The BD patients did not statistically differ from the schizophrenia patients in PPI or habituation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings of sensorimotor gating deficits among bipolar disorder patients are consistent with other findings using different measures of information processing and suggest that the neurobiological substrates underlying sensorimotor gating may be dysregulated during acute manic and psychotic states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California at San Diego, 200 West Arbor Drive, Mail Code 8218, La Jolla, CA 92093-8620, USA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minassian</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Feifel</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Braff</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 MH 42228</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004585" MajorTopicYN="N">Electrooculography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006185" MajorTopicYN="N">Habituation, Psychophysiologic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11566158</ArticleId><ArticleId IdType="pii">S0006322301011842</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(01)01184-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21839796</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2011</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The effect of comorbid anxiety disorder on neuropsychological function in bipolar II disorder.</ArticleTitle><Pagination><MedlinePgn>1841-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2011.07.013</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bipolar disorder (BP) is often comorbid with anxiety disorder (ANX), especially in bipolar II disorder (BP-II). BP patients with comorbid ANX often manifest intensified symptoms and harmful dysfunctions. However, most studies have focused on bipolar I disorder (BP-I); few have investigated the effect of comorbid ANX on the neuropsychological function of BP-II patients. We examined neuropsychological functions in BP-II patients with and without comorbid ANX.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-nine participants were recruited: 20 patients with interepisode (symptom-free) BP-II without comorbid ANX, 20 with interepisode BP-II with comorbid ANX, and 19 healthy controls. All participants were screened using the Chinese version of the Modified Schedule of Affective Disorder and Schizophrenia-Lifetime (SADS-L). Individuals comorbid with major or minor mental illness other than BP-II were excluded. Comparisons were made between the three groups using neuropsychological tests to assess memory, attention, psychomotor speed, and frontal executive function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BP-II patients with comorbid ANX showed poorer neuropsychological functions than those in the BP-II-only and control groups. Additionally, BP-II-only patients and controls showed equal cognitive performance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Because BP-II patients with comorbid ANX had the lowest scores in the majority of neuropsychological functional tests, we conclude that they have greater cognitive impairments than do BP-II patients without comorbid ANX. Neuropsychological dysfunctions seemed more strongly associated with ANX than with BP-II in interepisode periods. Identifying and managing ANX comorbidity is critical when treating BP-II patients.</AbstractText><CopyrightInformation>Copyright © 2011. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hsin-I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yun-Hsuan</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chun-Chieh</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jo Yung-Wei</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shiou-Lan</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Chun-Hsien</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>I Hui</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Tzung Lieh</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Tzeng</LastName><ForeName>Nian-Sheng</ForeName><Initials>NS</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>San-Yuan</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yen Kuang</ForeName><Initials>YK</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ru-Band</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21839796</ArticleId><ArticleId IdType="pii">S0278-5846(11)00243-0</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2011.07.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8217063</PMID><DateCompleted><Year>1993</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-5371</ISSN><JournalIssue CitedMedium="Print"><Issue>21</Issue><PubDate><Year>1993</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of psychiatry. Supplement</Title><ISOAbbreviation>Br J Psychiatry Suppl</ISOAbbreviation></Journal><ArticleTitle>Who responds to prophylactic lithium therapy?</ArticleTitle><Pagination><MedlinePgn>20-6</MedlinePgn></Pagination><Abstract><AbstractText>The search for predictors of outcome has not been particularly rewarding, and the use of lithium remains empirical: a trial of lithium is the most powerful predictor of outcome. However, lithium is a highly specific treatment for bipolar disorder. In non-bipolar affective disorder, factors of interest are correlates of bipolar disorder: mood-congruent psychotic features, retarded-endogenous profile, cyclothymic personality, positive family history of bipolar illness, periodicity, and normality between episodes of illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abou-Saleh</LastName><ForeName>M T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioural Science, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry Suppl</MedlineTA><NlmUniqueID>9001294</NlmUniqueID><ISSNLinking>0960-5371</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8217063</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1389048</PMID><DateCompleted><Year>1992</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-5371</ISSN><JournalIssue CitedMedium="Print"><Issue>18</Issue><PubDate><Year>1992</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The British journal of psychiatry. Supplement</Title><ISOAbbreviation>Br J Psychiatry Suppl</ISOAbbreviation></Journal><ArticleTitle>Family interaction versus individual psychopathology. Do they indicate the same processes in the families of schizophrenics?</ArticleTitle><Pagination><MedlinePgn>97-102</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, Los Angeles, CA 90024-1563.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talovic</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Nuechterlein</LastName><ForeName>K H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Fogelson</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Subotnik</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Asarnow</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH08744M</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH30911</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NG37705</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry Suppl</MedlineTA><NlmUniqueID>9001294</NlmUniqueID><ISSNLinking>0960-5371</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1389048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20004888</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7943</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of behavior therapy and experimental psychiatry</Title><ISOAbbreviation>J Behav Ther Exp Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Sleep, illness course, and concurrent symptoms in inter-episode bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>145-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbtep.2009.11.007</ELocationID><Abstract><AbstractText>We investigated associations between sleep, illness course, and concurrent symptoms in 21 participants with bipolar disorder who were inter-episode. Sleep was assessed using a week-long diary. Illness course and symptoms were assessed via validated semi-structured interviews. Lower and more variable sleep efficiency and more variable total wake time were associated with more lifetime depressive episodes. Variability in falling asleep time was positively correlated with concurrent depressive symptoms. Sleep efficiency was positively correlated with concurrent manic symptoms. These findings suggest that inter-episode sleep disturbance is associated with illness course and that sleep may be an important intervention target in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eidelman</LastName><ForeName>Polina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley, CA 94720-1650, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Lisa S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>June</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Allison G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R34 MH080958</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH080958-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Behav Ther Exp Psychiatry</MedlineTA><NlmUniqueID>0245075</NlmUniqueID><ISSNLinking>0005-7916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20004888</ArticleId><ArticleId IdType="pii">S0005-7916(09)00098-6</ArticleId><ArticleId IdType="doi">10.1016/j.jbtep.2009.11.007</ArticleId><ArticleId IdType="pmc">PMC2824048</ArticleId><ArticleId IdType="mid">NIHMS162388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Rhythms. 1997 Dec;12(6):627-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9406038</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1996 May;26(3):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8733206</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2006 Nov;29(11):1398-414</Citation><ArticleIdList><ArticleId IdType="pubmed">17162986</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Med Rev. 2009 Aug;13(4):275-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19269201</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jun;108(3):199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">18001840</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15625201</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2008 Apr;31(4):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18457236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2006 Sep;29(9):1155-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17040003</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1997 Nov;58(11):470-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9413412</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):209-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12738039</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Apr;60(4):221-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10221281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):103-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16542180</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):830-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18483132</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Apr;154(4):502-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9090337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2005;22(3):571-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16076655</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):448-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19685943</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1987 Feb;144(2):201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3812788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2006 Feb;29(2):193-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16494087</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2007 Oct 23;17(20):R877-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17956744</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19785919</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>955-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S003329170999136X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Attitudes and expectations about treatment have been associated with symptomatic outcomes, adherence and utilization in patients with psychiatric disorders. No measure of patients' anticipated benefits of treatment on domains of everyday functioning has previously been available.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Anticipated Benefits of Care (ABC) is a new, 10-item questionnaire used to measure patient expectations about the impact of treatment on domains of everyday functioning. The ABC was collected at baseline in adult out-patients with major depressive disorder (MDD) (n=528), bipolar disorder (n=395) and schizophrenia (n=447) in the Texas Medication Algorithm Project (TMAP). Psychometric properties of the ABC were assessed, and the association of ABC scores with treatment response at 3 months was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Evaluation of the ABC's internal consistency yielded Cronbach's alpha of 0.90-0.92 for patients across disorders. Factor analysis showed that the ABC was unidimensional for all patients and for patients with each disorder. For patients with MDD, lower anticipated benefits of treatment was associated with less symptom improvement and lower odds of treatment response [odds ratio (OR) 0.72, 95% confidence interval (CI) 0.57-0.87, p=0.0011]. There was no association between ABC and symptom improvement or treatment response for patients with bipolar disorder or schizophrenia, possibly because these patients had modest benefits with treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ABC is the first self-report that measures patient expectations about the benefits of treatment on everyday functioning, filling an important gap in available assessments of attitudes and expectations about treatment. The ABC is simple, easy to use, and has acceptable psychometric properties for use in research or clinical settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Warden</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9119, USA. Diane.Warden@UTSouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Carmody</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Gollan</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Kashner</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Crismon</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-1R18HS017189-01</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-53799</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-5R01MH064062-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006040" MajorTopicYN="Y">Goals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19785919</ArticleId><ArticleId IdType="pii">S003329170999136X</ArticleId><ArticleId IdType="doi">10.1017/S003329170999136X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29596661</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1469-5111</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>06</Month><Day>01</Day></PubDate></JournalIssue><Title>The international journal of neuropsychopharmacology</Title><ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial Agents for Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>550-569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ijnp/pyy018</ELocationID><Abstract><AbstractText Label="Background">Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.</AbstractText><AbstractText Label="Methods">This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.</AbstractText><AbstractText Label="Results">Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.</AbstractText><AbstractText Label="Conclusions">The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Círia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavarria</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Parc Sanitari San Joan de Déu, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vian</LastName><ForeName>João</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Melanie Maree</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marx</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Deakin University, Food &amp; Mood Centre, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Olivia May</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neuropsychopharmacol</MedlineTA><NlmUniqueID>9815893</NlmUniqueID><ISSNLinking>1461-1457</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29596661</ArticleId><ArticleId IdType="pii">4955527</ArticleId><ArticleId IdType="doi">10.1093/ijnp/pyy018</ArticleId><ArticleId IdType="pmc">PMC6007750</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Neurol. 2004 Jan;61(1):82-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14732624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16669715</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 1996 Dec;45(12):1798-804</Citation><ArticleIdList><ArticleId IdType="pubmed">8922368</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Jun;47(6):564-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23493756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2003 May;34(4):269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12662349</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E529-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15068957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Nov;32(3):197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">7852661</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):450-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15123489</ArticleId></ArticleIdList></Reference><Reference><Citation>An Acad Bras Cienc. 2015 Aug;87(2 Suppl):1361-73</Citation><ArticleIdList><ArticleId IdType="pubmed">26247148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):E14</Citation><ArticleIdList><ArticleId IdType="pubmed">24247871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2006 Aug;1074:261-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17105922</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2010 Oct;72 (8):763-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20716710</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10896698</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2009 Feb;21(1):138-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18925978</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Apr;65(4):386-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18391127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2006 Oct 20;127(2):397-408</Citation><ArticleIdList><ArticleId IdType="pubmed">17055439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Apr;21(2):171-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21486171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):644-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23507369</ArticleId></ArticleIdList></Reference><Reference><Citation>Biofactors. 1997;6(3):321-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9288403</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1990 Jun 29;169(3):851-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2114108</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurobiol Exp (Wars). 1996;56(2):597-609</Citation><ArticleIdList><ArticleId IdType="pubmed">8768311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2003 May;993:289-95; discussion 345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12853320</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2015 Aug;55:294-321</Citation><ArticleIdList><ArticleId IdType="pubmed">25957927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2002 Apr;959:199-213</Citation><ArticleIdList><ArticleId IdType="pubmed">11976197</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Behav Neurosci. 2011;5:187-200</Citation><ArticleIdList><ArticleId IdType="pubmed">25236556</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1989 Jan;154:48-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2673478</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2015 Jun;25(5):415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26091195</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Clin Psychopharmacol. 2008 Jun;16(3):199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">18540779</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1997 Mar 14;224(2):83-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9086462</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Mar;61(3):300-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14993118</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 2001 Jun;32(3):275-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11395173</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):132-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22212173</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2008 Apr;93(4):1433-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18211970</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Apr;67(4):360-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 Aug 18;336(8712):392-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1974941</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Sep 1;40(5):382-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8874839</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2002 Jan 15;1569(1-3):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11853951</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Nutr. 2015 Sep;54(6):1001-12</Citation><ArticleIdList><ArticleId IdType="pubmed">25296887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Regen Res. 2016 Oct;11(10 ):1564-1565</Citation><ArticleIdList><ArticleId IdType="pubmed">27904479</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Psychiatry. 2015 Jun 22;5(2):222-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26110123</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Dec 29;9(12):e115816</Citation><ArticleIdList><ArticleId IdType="pubmed">25546457</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1982 Jul;141:87-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7116078</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2007 Sep 10;570(1-3):97-107</Citation><ArticleIdList><ArticleId IdType="pubmed">17610872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1999 Feb;72(2):879-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9930766</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2000 Feb;71(2):614S-620S</Citation><ArticleIdList><ArticleId IdType="pubmed">10681269</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Jun;164(6):861-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17541043</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 Jan;33(1):194-203</Citation><ArticleIdList><ArticleId IdType="pubmed">17605107</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2007;9(1):71-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17599177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Inherit Metab Dis. 2016 Jan;39(1):47-58</Citation><ArticleIdList><ArticleId IdType="pubmed">26109258</ArticleId></ArticleIdList></Reference><Reference><Citation>Subcell Biochem. 2016;81:201-230</Citation><ArticleIdList><ArticleId IdType="pubmed">27830506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1986 Jan-Feb;10(1):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">2939126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Calcium. 2008 Jul;44(1):92-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18177933</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2004 Feb;77(2):303-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14751458</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Psychol Med. 2015 Jan-Mar;37(1):26-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25722508</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2014 Jul;257:95-105</Citation><ArticleIdList><ArticleId IdType="pubmed">24805071</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2002 Jan 11;290(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11779131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Dec;135(1-3):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21719110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Feb;4(1):61-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12047496</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):555-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17485607</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Rep Technol Assess (Summ). 2003 Aug;(64):1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12899148</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 2004 Dec;84(6):1041-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15533721</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1992 Sep;23(9):1312-7; discussion 1317-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1519288</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Dermatol. 2015 Oct;24(10 ):748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26010336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2001 May;49(5):561-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11357946</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014;167:306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25010374</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci. 2007 Jan 01;12:947-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17127351</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2014 Nov;24(11):1719-28</Citation><ArticleIdList><ArticleId IdType="pubmed">25224106</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Mar;141(3):448-50</Citation><ArticleIdList><ArticleId IdType="pubmed">6367496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11256685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol. 1991 Jan;46(1):M16-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1986037</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1995 Jun 29;50(1):123-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7605337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2002 Jun 8;359(9322):2039</Citation><ArticleIdList><ArticleId IdType="pubmed">12076581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Aug;18(5):440-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27566286</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2014 Jan 1;311(1):33-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24381967</ArticleId></ArticleIdList></Reference><Reference><Citation>Australas Psychiatry. 2017 Feb;25(1):13-14</Citation><ArticleIdList><ArticleId IdType="pubmed">27406927</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2014 Mar 19;348:g1888</Citation><ArticleIdList><ArticleId IdType="pubmed">24647162</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2015 Mar 17;590:52-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25637701</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Redox Rep. 2005;10(1):52-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15829111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2017 Jul 15;450:24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">28414049</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1990 Apr;38(4):473-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2329255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2000 Nov;48(5):723-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11079535</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2013;9:243-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23430979</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetol Metab Syndr. 2014 Jul 28;6(1):80</Citation><ArticleIdList><ArticleId IdType="pubmed">25104975</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2015 Mar 14;16:94</Citation><ArticleIdList><ArticleId IdType="pubmed">25873303</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Neurol Sci. 2013 Sep;40(5):628-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23968934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:92-109</Citation><ArticleIdList><ArticleId IdType="pubmed">19538689</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Feb 15;69(4):344-52</Citation><ArticleIdList><ArticleId IdType="pubmed">21167476</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Jan;47(1):26-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22711881</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11854529</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis. 2012;9(3):145-57</Citation><ArticleIdList><ArticleId IdType="pubmed">22327485</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 1996 Feb;36(1):193-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9011759</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1997 Sep;58(9):383-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9378688</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2010 Apr 9;86(4):639-49</Citation><ArticleIdList><ArticleId IdType="pubmed">20362274</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Clin Nutr Metab Care. 2015 Jul;18(4):367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">26049634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med Rep. 2012 Mar;5(3):680-2</Citation><ArticleIdList><ArticleId IdType="pubmed">22200861</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Sep 30;229(1-2):613-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26027439</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2013;775:29-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23392922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Nov;60(2):121-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10967371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 1989 Feb;9(1):2-19</Citation><ArticleIdList><ArticleId IdType="pubmed">2642915</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2013 Aug;1830(8):4117-29</Citation><ArticleIdList><ArticleId IdType="pubmed">23618697</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1392-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16020519</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2014 Jan;64:55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24269587</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2011 Dec;59(7):1003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21989390</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2011 Mar;26(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21380499</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Dev. 2006 Oct;28(9):576-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16737791</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1561-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18647623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Pharmacol. 1995 May;26(3):453-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7789717</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):56-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22230647</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Womens Ment Health. 2014 Jun;17(3):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24663685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2015 Jan;25(1):75-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23960204</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1998 Jun 15;796(1-2):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9689456</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Cutan Med Surg. 2012 Mar;31(1):11-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22361284</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2016 Feb;146(2):243-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26609167</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 May;31(3):189-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16699605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2016 Jul;26(7):911-23</Citation><ArticleIdList><ArticleId IdType="pubmed">26860546</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2017 Feb;71(2):77-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27800654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Oct;10(10):900-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16027739</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):353-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19166897</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2003 Feb 1;410(1):112-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12559983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2013 Dec;48(3):883-903</Citation><ArticleIdList><ArticleId IdType="pubmed">23761046</ArticleId></ArticleIdList></Reference><Reference><Citation>World Rev Nutr Diet. 2016;115:98-108</Citation><ArticleIdList><ArticleId IdType="pubmed">27198572</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2011 Jan;26(1):48-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20861739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2012 Mar;25(1):43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22467846</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Dec 15;230(2):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26350703</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurol Disord Drug Targets. 2016;15(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26553164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Nov;46(2):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9479613</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2016 Dec;77(12 ):e1610-e1617</Citation><ArticleIdList><ArticleId IdType="pubmed">27835719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Jun;16(4):410-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24636483</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Pharmacol Physiol. 2006 Aug;33(8):725-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16895547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2016 Feb 1;371(1):12-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26604131</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2004 Feb 15;36(4):423-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14975445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Aug;69(8):1203-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18557664</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1984 Aug;14(3):533-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6436854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):754-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17988366</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2009 Dec;120(6):441-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19392814</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Res. 2004 Jul;38(7):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15453632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 2007;(72):189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17982894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2013 Oct;33(5):627-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23948785</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Aug;167(8):942-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20595412</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2014 Jun;34(3):413-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24699040</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Aug;189:124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16880481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Biol Interact. 2006 Oct 27;163(1-2):94-112</Citation><ArticleIdList><ArticleId IdType="pubmed">16765926</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Mol Med. 2014 Apr 06;6(6):721-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24711540</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2012 Aug 14;10:91</Citation><ArticleIdList><ArticleId IdType="pubmed">22891797</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2015 Jan-Mar;37(1):3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">25295681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2016 Mar;1367(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26971083</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets. 2016;17 (13):1527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27527619</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2007;21(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17190525</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Oct 15;221:275-282</Citation><ArticleIdList><ArticleId IdType="pubmed">28662460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jan;73(1):37-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21903028</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2015 Mar 10;22(8):679-85</Citation><ArticleIdList><ArticleId IdType="pubmed">25386668</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2002 Apr;34(4):348-57</Citation><ArticleIdList><ArticleId IdType="pubmed">11854034</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Appl Pharmacol. 2002 Jul 1;182(1):84-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12127266</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2003 Mar;26(3):137-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12591216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2004 Jan;36(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14675124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1997 Mar;77(1):283-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9044393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2011 Sep 30;286(39):33804-10</Citation><ArticleIdList><ArticleId IdType="pubmed">21840998</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2014 Jun 6;269:143-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24680856</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Jul;69(7):836-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22431837</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2006 Jan 18;78(8):803-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16253281</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:304-13</Citation><ArticleIdList><ArticleId IdType="pubmed">24184687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Oct;68(4):503-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20976769</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurol Disord Drug Targets. 2014;13(5):817-27</Citation><ArticleIdList><ArticleId IdType="pubmed">25012620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1993 Sep;118(2):181-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8229067</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1998 Sep;12(12):1183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9737721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med. 2009 Jan-Feb;15(1-2):43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19011689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Neuroanat. 2005 Jan;29(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15589699</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1992;109(4):489-96</Citation><ArticleIdList><ArticleId IdType="pubmed">1365868</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Jan 29;285:281-91</Citation><ArticleIdList><ArticleId IdType="pubmed">25463525</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2015 Feb 04;11:279-89</Citation><ArticleIdList><ArticleId IdType="pubmed">25678793</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1999 Sep;277(3 Pt 2):R698-704</Citation><ArticleIdList><ArticleId IdType="pubmed">10484486</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2012 Apr;15(3):417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">21859514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Mar 6;273(10):5678-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9488698</ArticleId></ArticleIdList></Reference><Reference><Citation>Altern Med Rev. 2008 Sep;13(3):216-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18950248</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2002 Nov;76(5):1151S-7S</Citation><ArticleIdList><ArticleId IdType="pubmed">12418493</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2005 Nov 9;1061(2):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16256963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrients. 2014 Apr 11;6(4):1501-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24732019</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biomed Sci. 2008 Jun;4(2):89-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23675073</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Feb;202:100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23377209</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2009 Feb;89(2):702S-6S</Citation><ArticleIdList><ArticleId IdType="pubmed">19141696</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1997;61(8):805-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9275010</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1988 Jun 30;318(26):1720-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3374544</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2001 Mar;30(2):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11270481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2004 Oct-Dec;25(5-6):551-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15363641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Nov;14(7):707-18</Citation><ArticleIdList><ArticleId IdType="pubmed">22897629</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2012 Jan;1821(1):241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21763457</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2007 Oct 8;18(15):1567-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17885603</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Aug;177(2):575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2014;38(1):111-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24077434</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):185-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10800742</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Jan;208(1):78-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25999335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Nutr. 1992 Apr;11(2):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1578091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):300-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12895208</ArticleId></ArticleIdList></Reference><Reference><Citation>Horm Mol Biol Clin Investig. 2014 May;18(2):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">25390004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2016 Apr;77(4):e457-66</Citation><ArticleIdList><ArticleId IdType="pubmed">27137430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2006 Oct 6;127(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17018277</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Res Commun. 1991;15(5):255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1666623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak J Biol Sci. 2015 Jan;18(1):11-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26353411</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2018 Jan;72 (1):35-44</Citation><ArticleIdList><ArticleId IdType="pubmed">29064136</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Health Aging. 1999;3(1):5-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10888476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr J. 2013 Mar 09;12:31</Citation><ArticleIdList><ArticleId IdType="pubmed">23510529</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1981 May;11(2):249-56</Citation><ArticleIdList><ArticleId IdType="pubmed">6791192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):628-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17845278</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscle Nerve. 2007 Feb;35(2):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17080429</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 2013 May;31(3):165-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23286972</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12751049</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jan 10;144(1-2):141-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22963894</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2016 May 19;3(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">27257625</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Dec;169(12 ):1267-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23212058</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Mar 15;65(6):489-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19103439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol B Psychol Sci Soc Sci. 2001 Nov;56(6):P327-39</Citation><ArticleIdList><ArticleId IdType="pubmed">11682586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Jun;78(6):e656-e667</Citation><ArticleIdList><ArticleId IdType="pubmed">28682528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Jan 1;207 :429-433</Citation><ArticleIdList><ArticleId IdType="pubmed">27794238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2005 Aug;1053:153-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16179519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Adh Migr. 2009 Jan-Mar;3(1):129-37</Citation><ArticleIdList><ArticleId IdType="pubmed">19372744</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Jan 06;5:e492</Citation><ArticleIdList><ArticleId IdType="pubmed">25562842</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Histochem. 2016 Apr;118(3):286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26948666</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Jun 30;123(2):87-100</Citation><ArticleIdList><ArticleId IdType="pubmed">12850248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2002 Jun;132(6):1345-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12042457</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Bras Psiquiatr. 2011 Dec;33(4):374-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22189927</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Oct;171(10):1067-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24935197</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Chem. 2016 Apr;397(4):283-96</Citation><ArticleIdList><ArticleId IdType="pubmed">26859499</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Sep 15;64(6):468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18534556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Dec;1031:249-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15753151</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2007 Jul;61(7):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17568057</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jun;34(7):1810-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19194376</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 2012 Jan;95(1):194-203</Citation><ArticleIdList><ArticleId IdType="pubmed">22170358</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2005 Dec;30(12):1615-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16362781</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Neuroanat. 1999 Feb;16(2):135-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10223312</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1870-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11854487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Mar;50:36-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24332923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endocrinol. 2016 Dec;231(3):235-244</Citation><ArticleIdList><ArticleId IdType="pubmed">27803236</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 May 14;8(5):e52147</Citation><ArticleIdList><ArticleId IdType="pubmed">23690912</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Jan;134(Pt 1):210-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20929961</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1990 Jan 15;27(2):125-37</Citation><ArticleIdList><ArticleId IdType="pubmed">2294976</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2012 Oct;66(6):514-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23066769</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Biol Med (Maywood). 2016 Mar;241(6):620-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26785711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):317-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20800897</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pineal Res. 2005 Jan;38(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15617531</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2014 Mar;99(3):757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">24423304</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2013 Mar;34(3):167-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23369637</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1993 Jun;264(6 Pt 1):E855-62</Citation><ArticleIdList><ArticleId IdType="pubmed">8333511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31482650</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Increased plasma levels of 8-oxoguanine DNA glycosylase-1 in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>719-720</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12928</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceylan</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1438-8240</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Dokuz Eylul University, Health Sciences Institute, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yılmaz</LastName><ForeName>Selda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Dokuz Eylul University, Health Sciences Institute, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bora</LastName><ForeName>Uğur</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Dokuz Eylul University, Health Sciences Institute, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuna</LastName><ForeName>Gamze</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ildız</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Dokuz Eylul University, Health Sciences Institute, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akan</LastName><ForeName>Pınar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldic</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Özerdem</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5614-64-2</RegistryNumber><NameOfSubstance UI="C024829">8-hydroxyguanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Z93L87A1R</RegistryNumber><NameOfSubstance UI="D006147">Guanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.-</RegistryNumber><NameOfSubstance UI="D045647">DNA Glycosylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.-</RegistryNumber><NameOfSubstance UI="C479058">oxoguanine glycosylase 1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045647" MajorTopicYN="N">DNA Glycosylases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006147" MajorTopicYN="N">Guanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31482650</ArticleId><ArticleId IdType="doi">10.1111/pcn.12928</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Brown N, Andreazza A, Young L. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014; 218: 61-68.</Citation></Reference><Reference><Citation>Dizdaroglu M. Oxidatively induced DNA damage: Mechanisms, repair and disease. Cancer Lett. 2012; 327: 26-47.</Citation></Reference><Reference><Citation>Munkholm K, Peijs L, Vinberg M, Kessing LV. A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Transl. Psychiatry 2015; 5: e614.</Citation></Reference><Reference><Citation>Ceylan D, Tuna G, Kirkali G et al. Oxidatively-induced DNA damage and base excision repair in euthymic patients with bipolar disorder. DNA Repair (Amst) 2018; 65: 64-72.</Citation></Reference><Reference><Citation>Ceylan D, Scola G, Tunca Z et al. DNA redox modulations and global DNA methylation in bipolar disorder: Effects of sex, smoking and illness state. Psychiatry Res 2018; 261: 589-596.</Citation></Reference><Reference><Citation>Czarny P, Wigner P, Galecki P, Sliwinski T. The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. Prog. Neuro-Psychopharmacology Biol. Psychiatry 2018; 80: 309-321.</Citation></Reference><Reference><Citation>de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol. Biosyst 2009; 5: 1512-1526.</Citation></Reference><Reference><Citation>Tissue expression of OGG1. Summary - The Human Protein Atlas. [Cited 9 August 2019.] Available from URL: https://www.proteinatlas.org/ENSG00000114026-OGG1/tissue</Citation></Reference><Reference><Citation>Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54: 5801-5803.</Citation></Reference><Reference><Citation>Hakim IA, Harris R, Garland L, Cordova CA, Mikhael DM, Sherry Chow H-H. Gender difference in systemic oxidative stress and antioxidant capacity in current and former heavy smokers. Cancer Epidemiol. Biomarkers Prev 2012; 21: 2193-2200.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25020078</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Editorial.</ArticleTitle><Pagination><MedlinePgn>353-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/15622975.2014.936141</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25020078</ArticleId><ArticleId IdType="doi">10.3109/15622975.2014.936141</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">443476</PMID><DateCompleted><Year>1979</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>136</Volume><Issue>6</Issue><PubDate><Year>1979</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Appearance of manic psychosis following rapid normalization of thyroid status.</ArticleTitle><Pagination><MedlinePgn>846-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>T B</ForeName><Initials>TB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">443476</ArticleId><ArticleId IdType="doi">10.1176/ajp.136.6.846</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4849927</PMID><DateCompleted><Year>1974</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>219</Volume><Issue>2</Issue><PubDate><Year>1974</Year></PubDate></JournalIssue><Title>Archiv fur Psychiatrie und Nervenkrankheiten</Title><ISOAbbreviation>Arch Psychiatr Nervenkr (1970)</ISOAbbreviation></Journal><ArticleTitle>[The loneliness experience in the course of endogenous psychosis (author's transl)].</ArticleTitle><Pagination><MedlinePgn>159-77</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czernik</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Steinmeyer</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Beurteilung des Einsamkeitserlebens im Verlauf endogener Psychosen</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arch Psychiatr Nervenkr (1970)</MedlineTA><NlmUniqueID>1270313</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005120" MajorTopicYN="N">Extraversion, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012934" MajorTopicYN="Y">Social Isolation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4849927</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21111407</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>5</Issue><PubDate><MedlineDate>2011 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Patterns of comorbidity among mental disorders: a person-centered approach.</ArticleTitle><Pagination><MedlinePgn>527-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2010.10.006</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Comorbidity poses a major challenge to conventional methods of diagnostic classification. Although dimensional models of psychopathology have shed some light on this issue, the reason for interrelationships among dimensions is unclear. The current study employed an alternative approach to characterizing patterns of comorbidity among common mental disorders by modeling them instead as clusters by using latent class analysis (LCA).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Latent class analyses of Diagnostic and Statistical Manual of Mental Disorders diagnoses from two nationally representative epidemiological samples--the National Comorbidity Survey and National Comorbidity Survey--Replication datasets--were undertaken.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within each dataset, LCA yielded 5 latent classes exhibiting distinctive profiles of diagnostic comorbidity: a fear class (all phobias and panic disorder), a distress class (depression, generalized anxiety disorder, dysthymia), an externalizing class (alcohol and drug dependence, conduct disorder), a multimorbid class (highly elevated rates of all disorders), and a few-disorders class (very low probability of all disorders). Whereas some disorders were relatively specific to certain classes, others (major depression, posttraumatic stress disorder, social phobia) appeared to be evident across all classes. Profiles for the five classes were highly similar across the two samples. When bipolar I disorder was added to the LCA models, in both samples, it occurred almost exclusively in the multimorbid class.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Comorbidity among mental disorders in the general population appears to occur in a finite number of distinct patterns. This finding has important implications for efforts to refine existing diagnostic classification schemes, as well as for research directed at elucidating the etiology of mental disorders.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaidyanathan</LastName><ForeName>Uma</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychology, Florida State University, Tallahassee, FL 32306, USA. uma@psy.fsu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrick</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Iacono</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA013240-10</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH072850</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH065137</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA024417-05</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA005147-20</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 072850</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DA005147</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 65137</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA013240</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 089727</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA005147</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH065137-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH089727</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA024417</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA 024417</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA024417</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH089727-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA 05147</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA 13240</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21111407</ArticleId><ArticleId IdType="pii">S0010-440X(10)00173-2</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2010.10.006</ArticleId><ArticleId IdType="pmc">PMC3110544</ArticleId><ArticleId IdType="mid">NIHMS256561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 2009 Dec;39(12):2001-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19796426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma Stress. 2005 Feb;18(1):23-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16281192</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2083-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19796434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2002 Aug;111(3):411-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12150417</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Dec;59(12):1125-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12470129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2004 Nov;113(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15535795</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2099-103</Citation><ArticleIdList><ArticleId IdType="pubmed">19796433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2005 Nov;114(4):522-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16351375</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jul;167(7):745-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20595426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1994 Jan-Feb;28(1):57-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8064641</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2025-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19796428</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Oct;56(10):921-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10530634</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2003 Jun;15(2):205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12847781</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):1993-2000</Citation><ArticleIdList><ArticleId IdType="pubmed">19796425</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2071-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19796430</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2043-59</Citation><ArticleIdList><ArticleId IdType="pubmed">19796429</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569893</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2004;13(2):60-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15297904</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2061-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19796431</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2005 Jan-Feb;67(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15673617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Child Psychol. 2008 Apr;36(3):433-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17965930</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 1998;49:377-412</Citation><ArticleIdList><ArticleId IdType="pubmed">9496627</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Mar;186:182-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15738496</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2004;13(2):69-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15297905</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1998 Oct;173:312-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9926035</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Sci. 2010 Jun;33(2-3):137-50; discussion 150-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20584369</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2091-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19796432</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Jun;58(6):597-603</Citation><ArticleIdList><ArticleId IdType="pubmed">11386990</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jan;160(1):4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12505793</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jul;60(7):709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12860775</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2004 Feb;3(1):24-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16633445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):929-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12963675</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Dec;39(12):2013-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19796427</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Nov;36(11):1593-600</Citation><ArticleIdList><ArticleId IdType="pubmed">16882356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24364600</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1939-1846</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of abnormal psychology</Title><ISOAbbreviation>J Abnorm Psychol</ISOAbbreviation></Journal><ArticleTitle>Real-world emotion? An experience-sampling approach to emotion experience and regulation in bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>971-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1037/a0034425</ELocationID><Abstract><AbstractText>Laboratory studies suggest that bipolar disorder is characterized by emotion dysregulation, yet emotion disturbance has not been systematically described using more ecologically valid methods. Using an experience-sampling approach, we therefore sought to investigate positive and negative emotionality, emotion regulation strategies, and functioning among remitted individuals with bipolar I disorder (BD; n = 31) compared with both healthy controls (CTL; n = 32) and remitted individuals with major depressive disorder (MDD; n = 21). Hierarchical linear modeling analyses of self-report data spanning a 6-day consecutive period revealed that the BD group aligned with the CTL group in reporting greater positive emotionality than the MDD group, but aligned with the MDD group in reporting greater negative emotionality than the CTL group. Furthermore, the BD and MDD groups reported greater general use of emotion regulation strategies than the CTL group. These findings suggest that BD is characterized by amplified emotionality as well as increased efforts to regulate emotions in everyday life. Discussion focuses on implications for BD, as well as identification of unique (disorder-specific) and shared (transdiagnostic) features of emotion disturbance.</AbstractText><CopyrightInformation>PsycINFO Database Record (c) 2013 APA, all rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>June</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogan</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mennin</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychology, City University of New York, Hunter College.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychology, Swinburne University of Technology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Abnorm Psychol</MedlineTA><NlmUniqueID>0034461</NlmUniqueID><ISSNLinking>0021-843X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24364600</ArticleId><ArticleId IdType="pii">2013-44247-004</ArticleId><ArticleId IdType="doi">10.1037/a0034425</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2115895</PMID><DateCompleted><Year>1990</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>1990</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Refractoriness to lithium treatment in bipolar mania.</ArticleTitle><Pagination><MedlinePgn>227</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tanenbaum</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ritvo</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2115895</ArticleId><ArticleId IdType="doi">10.1097/00004714-199006000-00021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20856191</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>The bipolar spectrum: do we need a single algorithm for affective disorders?</ArticleTitle><Pagination><MedlinePgn>450-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agius</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bugler</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tavormina</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003511">Cyclohexanols</NameOfSubstance></Chemical><Chemical><RegistryNumber>7D7RX5A8MO</RegistryNumber><NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003511" MajorTopicYN="N">Cyclohexanols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20856191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7982857</PMID><DateCompleted><Year>1994</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>1994</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Listening to psychotherapy.</ArticleTitle><Pagination><MedlinePgn>1079</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>J F</ForeName><Initials>JF</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7982857</ArticleId><ArticleId IdType="pii">S0890-8567(09)64111-3</ArticleId><ArticleId IdType="doi">10.1097/00004583-199410000-00002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17988359</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Early age at onset of bipolar disorder is associated with more severe clinical features but delayed treatment seeking.</ArticleTitle><Pagination><MedlinePgn>698-705</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our aim was to obtain a comprehensive view of differences between bipolar disorder (BD) patients with onset at early versus adult age in a representative study cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the Jorvi Bipolar Study (JoBS), 1,630 psychiatric in- and outpatients were systematically screened for BD using the Mood Disorder Questionnaire (MDQ). A total of 191 bipolar I and II patients with a current DSM-IV episode were interviewed to obtain information about age at onset of mood symptoms, clinical course, treatment, comorbidity, and functional status. The patients were classified as either early onset (&lt;18 years) or adult onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One-third of subjects with BD (58/191, 30%) had early onset. This was associated with female gender, more lifetime psychotic symptoms, greater overall comorbidity, and a greater length of time from first episode to treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although BD patients with early age at onset have more severe clinical features and illness course, the delays from first episode to treatment and to correct diagnosis are longer than for those with adult onset disorder. To reduce morbidity rates related to the most severe forms of BD, the recognition and diagnosis of BD during adolescence needs to be improved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suominen</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. kirsi.suominen@ktl.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantere</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Valtonen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Arvilommi</LastName><ForeName>Petri</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Leppämäki</LastName><ForeName>Sami</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Paunio</LastName><ForeName>Tiina</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Isometsä</LastName><ForeName>Erkki</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17988359</ArticleId><ArticleId IdType="pii">BDI388</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00388.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25524085</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The longitudinal course of sleep timing and circadian preferences in adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>392-402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12286</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To study the longitudinal course of sleep timing and circadian preferences in individuals with bipolar disorder (BP) compared to individuals with non-BP psychopathology and healthy controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Individuals with bipolar I and bipolar II disorder (n = 257), non-BP psychopathology (n = 105), and healthy controls (n = 55) (mean age 40.2 years, 21.3% male, 85.1% Caucasian) were followed on average every 27 months for a mean of four years. Sleep timing parameters and circadian preference were reported using the Sleep Timing Questionnaire and The Composite Scale for Morningness. Group comparisons were adjusted for multiple comparisons and between-group differences in demographic variables and psychopharmacological treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Regardless of their current mood state, individuals with BP showed more sleep onset latency (SOL), wakening after sleep onset (WASO), and evening preference in comparison to both individuals with non-BP psychopathology and healthy controls. Individuals with BP also showed less stability of bed and awakening times in comparison to the other two groups, though these results were dependent on mood state. Non-BP individuals only showed more WASO and less stability in bed and awakening times before work/school days than healthy controls. Adjusting for comorbid disorders yielded similar results. Within-group analyses found little to no effect of time and BP subtype on sleep timing and circadian preference.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Disturbances of sleep timing are prominent in individuals with BP. These disturbances are worse during mood episodes, but still apparent during euthymic periods. Evening preference was not associated with polarity type, or mood state in BP, suggesting that this characteristic may be a trait marker.</AbstractText><CopyrightInformation>© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seleem</LastName><ForeName>Mohammad A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merranko</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Tina R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto Faculty of Medicine, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Nationwide Children's Hospital and The Ohio State College of Medicine, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimgaonkar</LastName><ForeName>Vishwajit L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diler</LastName><ForeName>Rasim S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakolsky</LastName><ForeName>Dara J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 TW009114</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#MH-060952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020178" MajorTopicYN="N">Sleep Disorders, Circadian Rhythm</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">circadian</Keyword><Keyword MajorTopicYN="N">eveningness</Keyword><Keyword MajorTopicYN="N">morningness</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25524085</ArticleId><ArticleId IdType="doi">10.1111/bdi.12286</ArticleId><ArticleId IdType="pmc">PMC4458164</ArticleId><ArticleId IdType="mid">NIHMS644811</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 2012 Apr;200(4):308-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22194182</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Chronobiol. 1976;4(2):97-110</Citation><ArticleIdList><ArticleId IdType="pubmed">1027738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Apr;158:1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24655758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2007;9(3):333-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17969870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2012 Aug;26(8):1108-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21965189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2014 Jan;76(1):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24360143</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2008 Nov 14;445(2):184-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18789374</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2014;15:24</Citation><ArticleIdList><ArticleId IdType="pubmed">24433249</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Apr 30;166(2-3):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19278733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):160-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16542186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2004 May;21(3):435-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15332448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):256-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18271904</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2013 Oct;54(7):1003-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23702535</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2003 Mar 15;26(2):208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12683481</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Nov;134(1-3):416-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21683450</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Aug 1;66(3):298-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19358978</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci (Schol Ed). 2014;6:120-37</Citation><ArticleIdList><ArticleId IdType="pubmed">24389266</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1047-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18228528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sleep Res. 2000 Jun;9(2):117-27</Citation><ArticleIdList><ArticleId IdType="pubmed">10849238</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2009 Dec;11(6):488-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19909672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2006;23(1-2):485-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16687321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Jun;8(3):271-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16696829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2005;22(3):571-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16076655</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):830-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18483132</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2007;24(4):589-97</Citation><ArticleIdList><ArticleId IdType="pubmed">17701674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Jun;80(2-3):145-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15207927</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Circadian Rhythms. 2009 Jan 23;7:2</Citation><ArticleIdList><ArticleId IdType="pubmed">19166596</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2007 Sep;17(9):587-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17512705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):918-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18076544</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Apr;198(4):269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">21263013</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2005 Sep 15;136(2-3):153-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16125786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med. 2005;37(3):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">16019718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):209-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12738039</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 May;39(5):559-65</Citation><ArticleIdList><ArticleId IdType="pubmed">6124223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2014 Jun;31(5):698-704</Citation><ArticleIdList><ArticleId IdType="pubmed">24625313</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1987 Feb;144(2):201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3812788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):271-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18271906</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2006 Mar;5(2):150-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16507006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sleep Res. 2002 Sep;11(3):183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12220313</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2009;56 Suppl 1:91-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18644396</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Breath. 2010 Jun;14(2):153-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19774406</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Apr 5;141B(3):234-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16528748</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15625201</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Res Health. 2001;25(2):94-100</Citation><ArticleIdList><ArticleId IdType="pubmed">11584555</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Neurosci. 2001 Aug;115(4):895-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11508728</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2009;9:70</Citation><ArticleIdList><ArticleId IdType="pubmed">19909500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Breath. 2009 May;13(2):169-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18982372</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychotherapy (Chic). 2014 Mar;51(1):180-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24377402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2011 May;23(2):113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21547271</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2001;27(3):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">11596850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2007;24(5):921-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17994346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Mar 20;146(1):112-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22884237</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Nov 8;218(3):153-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8945751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Psychol. 1989 Oct;74(5):728-38</Citation><ArticleIdList><ArticleId IdType="pubmed">2793773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27137894</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms.</ArticleTitle><Pagination><MedlinePgn>199-206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12580</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The objective of this study was to assess the strengths and limitations of a mixed bipolar depression definition made more inclusive than that of the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) by counting not only 'non-overlapping' mood elevation symptoms (NOMES) as in DSM-5, but also 'overlapping' mood elevation symptoms (OMES, psychomotor agitation, distractibility, and irritability).</AbstractText><AbstractText Label="METHODS">Among bipolar disorder (BD) out-patients assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, we assessed prevalence, demographics, and clinical correlates of mixed vs. pure depression, using more inclusive (≥3 NOMES/OMES) and less inclusive DSM-5 (≥3 NOMES) definitions.</AbstractText><AbstractText Label="RESULTS">Among 153 depressed BD, counting not only NOMES but also OMES yielded a three-fold higher mixed depression rate (22.9% vs. 7.2%) and important statistically significant clinical correlates for mixed compared to pure depression (more lifetime anxiety disorder comorbidity, more current irritability, and less current antidepressant use), which were not significant using the DSM-5 threshold.</AbstractText><AbstractText Label="CONCLUSION">To conclude, further studies with larger numbers of patients with DSM-5 bipolar mixed depression assessing strengths and limitations of more inclusive mixed depression definitions are warranted, including efforts to ascertain whether or not OMES should count toward mixed depression.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ilsan Paik Hospital, Inje University School of Medicine, Goyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Seoul Paik Hospital, Inje University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citrome</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>New York Medical College, Valhalla, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Centre, University of California and Veterans Administration Hospital, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goffin</LastName><ForeName>K C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>J N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooshmand</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>P W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>T A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">diagnosis</Keyword><Keyword MajorTopicYN="Y">nosology</Keyword><Keyword MajorTopicYN="Y">psychopathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27137894</ArticleId><ArticleId IdType="doi">10.1111/acps.12580</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">667233</PMID><DateCompleted><Year>1978</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>1978</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Circadian rhythm disorders in manic-depressives.</ArticleTitle><Pagination><MedlinePgn>335-51</MedlinePgn></Pagination><Abstract><AbstractText>Seven circular manic-depressives were studied through complete of cycles of mania and depression. In five subjects, there was evidence that a circadian rhythm free-ran fast (p less than 0.005 and p less than 0.002 in two of the subjects), and in five subjects, there was evidence that lithium slowed a circadian rhythm. The palliative benefit of lithium may derive from slowing or delaying an overfast circadian clock to prevent desynchronization. Two subjects whose circadian clocks seemed too slow were lithium nonresponders (p less than 0.05). As circadian clock frequency may be transmitted on an X-chromosome gene and may increase with age, a circadian etiology is consistent with the genetics and age distribution of manic-depressive illness. Affective disturbances could be evolutionary remnants of the photo-periodic seasonal responses in animals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kripke</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Mullaney</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">667233</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16649836</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>473-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To conduct the first randomized, controlled trial assessing the prophylactic efficacy of gabapentin in bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a 1-year, double-blind, randomized, comparative, placebo-controlled, parallel-group, multicenter study. As this was a pure prophylactic trial, only euthymic bipolar I and II patients (DSM-IV) were randomly assigned in a 1:1 ratio to gabapentin (N = 13) or placebo (N = 12) added to the current treatment (lithium, valproate, carbamazepine, or any combination but not antipsychotics or antidepressants). Subjects participated in the study for 12 months. The primary efficacy parameter was the Clinical Global Impressions scale for Bipolar Illness, Modified (CGI-BP-M), which was assessed at all visits. Other assessments were the Young Mania Rating Scale (YMRS), Hamilton Rating Scale for Depression (HAM-D), Hamilton Rating Scale for Anxiety (HAM-A), Pittsburgh Sleep Quality Index (PSQI), and the systematic collection of reported adverse events. Data were collected from May 1999 to February 2004.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The change from baseline to month 12 in mean CGI-BP-M scores between groups was statistically significant (p = .0046). Mean score change from baseline to endpoint in the gabapentin group was -2.1, and the mean score change in the placebo group was -0.6. No emerging manic or depressive symptoms were seen in either group as measured with the YMRS, HAM-D, HAM-A, and PSQI. In the PSQI-6 subscale (use of sleeping medication), the mean score change at month 12 in the gabapentin group was 0.9, and the mean score change in the placebo group was 0.05 (p = .0267). Overall, gabapentin was well tolerated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This small, randomized clinical trial comparing the prophylactic efficacy of adjunctive gabapentin to placebo suggests that, despite lack of acute efficacy, treatment with gabapentin might provide some benefit on the long-term outcome of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain. evieta@clinic.ub.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel Goikolea</LastName><ForeName>José</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>Anabel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Comes</LastName><ForeName>Mercè</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Verger</LastName><ForeName>Katia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Masramon</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Sanchez-Moreno</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="N">Cyclohexanecarboxylic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16649836</ArticleId><ArticleId IdType="doi">10.4088/jcp.v67n0320</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20141803</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>36 Suppl 1</Volume><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Depressive onset episode of bipolar disorder: clinical and prognostic considerations].</ArticleTitle><Pagination><MedlinePgn>S18-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(10)70005-1</ELocationID><Abstract><AbstractText>Both retrospective and high-risk individuals prospective studies show that a high percentage of patients experience one or more depressive episodes previous the diagnosis of bipolar disorder. Depressive onset bipolar disorders begin earlier than the ones with a manic onset, have a higher duration, a chronic course with frequent recurrences, a depressive dominant polarity, a higher lifetime rate of suicidal behaviour, less psychotic symptoms and more rapid cycling. A relation between frequent rapid cycling and previous prescription of antidepressants was suggested but not rigorously demonstrated. Thus, a high percentage of patients presenting a first depressive episode will later develop bipolar disorder. Several risk factors of bipolarity have been identified and might be detected during each depressive episode by using standardised evaluations and family interviews, if necessary. Among them, an early age at first episode, frequent recurrences, a family history of bipolar disorder, atypical features and hypomanic symptoms are particularly associated with the subsequent development of a bipolar disorder. The impact of a high risk of bipolarity on drug prescription is unclear ; however, one can strongly recommend to intensifying clinical monitoring and to proposing adjunctive psychoeducation.</AbstractText><CopyrightInformation>Copyright (c) 2010 L'Encéphale. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Besnier</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pôle de Psychiatrie Adultes, CHU Sainte Marguerite, 13009 Marseille. nathalie.besnier@ap-hm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fakra</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Adida</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Maurel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Premier épisode dépressif d'un trouble bipolaire: aspects cliniques et pronostiques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>20</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20141803</ArticleId><ArticleId IdType="pii">S0013-7006(10)70005-1</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(10)70005-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21077387</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2200</ISSN><JournalIssue CitedMedium="Print"><Volume>117</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nederlands tijdschrift voor tandheelkunde</Title><ISOAbbreviation>Ned Tijdschr Tandheelkd</ISOAbbreviation></Journal><ArticleTitle>[Bipolar disorders and oral health].</ArticleTitle><Pagination><MedlinePgn>493-9</MedlinePgn></Pagination><Abstract><AbstractText>A bipolar disorder is a mood disorder characterized by recurrent occurrences of manic, depressive or mixed episodes, separated by shorter or longer relatively symptom-free periods. In the Netherlands, the incidence of bipolar disorders is 1.9%. Bipolar disorders are usually treated with a combination of psycho-education, self-management and pharmacotherapy. Both the bipolar disorder and the drugs for treating this disorder have negative effects on oral health. Patients have, among other things, an increased risk of caries, xerostomia, taste abnormalities and bruxism. Extensive instruction in oral hygiene, supported frequently by professional oral health care, is therefore essential. Considering the possible interaction among different kinds of drugs, NSAIDs should only be prescribed after consulting the patient's psychiatrist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>P F J</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Uit het Behandelcentrum bipolaire stoornissen, divisie kortdurende psychiatrie, GGZ Noord-Holland-Noord. r.schulte@ggz-nhn.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Bipolaire stoornissen en mondgezondheid.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Tandheelkd</MedlineTA><NlmUniqueID>0400771</NlmUniqueID><ISSNLinking>0028-2200</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>D</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017742" MajorTopicYN="Y">Dental Care for Chronically Ill</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003731" MajorTopicYN="N">Dental Caries</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009910" MajorTopicYN="Y">Oral Hygiene</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21077387</ArticleId><ArticleId IdType="doi">10.5177/ntvt.2010.10.10165</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22401488</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2012</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risk factors for antidepressant-related switch to mania.</ArticleTitle><Pagination><MedlinePgn>e271-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.11m07166</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Treatment of bipolar depression with antidepressants is strongly debated on the basis of the methodologically poor and insufficient data supporting their use and the widely held belief that antidepressants can induce new episodes of abnormal mood elevation or accelerate the rate of cycling. The present study aimed at identifying clinical risk factors for switch into hypomania, mania, or mixed states, within 8 weeks after introduction of an antidepressant or after increasing its dosage, in a prospective, longitudinal design.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">221 consecutive DSM-IV-TR depressed bipolar I and II disorder patients were treated with antidepressants, which were added to previously prescribed mood stabilizers and/or atypical antipsychotics. No patient was on antidepressant monotherapy. The patients were enrolled from October 2005 through January 2010. The primary outcome was the assessment of switch to mania or hypomania within 8 weeks after the introduction or dose increase of an antidepressant. Both groups were compared with analysis of variance and χ² procedures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment-emergent affective switch was detected in 54 patients (24.4%) (switch group) while 167 patients (75.6%) (nonswitch group) did not experience a treatment-related switch. The main clinical differences significantly associated with the occurrence of an antidepressant-related switch, after performing logistic regression analysis, were higher rate of previous switches (P &lt; .001) in the switch versus the nonswitch group, lower rate of responses to antidepressants (P &lt; .001) in the switch versus the nonswitch group, and earlier age at onset (P = .026) in the switch versus the nonswitch group.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Bipolar patients with an earlier age at onset and an illness course characterized by lower rate of response to antidepressants and higher rate of switches into mania or hypomania were found to be the ones with higher switch risk. Nevertheless, a greater number of previous antidepressant exposures was not associated with the occurrence of an antidepressant-associated switch.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01503489.</AbstractText><CopyrightInformation>© Copyright 2012 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valentí</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institute of Neuroscience, Hospital Clinic Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bonnín</LastName><ForeName>C Mar</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Adriane R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nivoli</LastName><ForeName>Alessandra M A</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>José Manuel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Undurraga</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01503489</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22401488</ArticleId><ArticleId IdType="doi">10.4088/JCP.11m07166</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11874212</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Demographic and clinical characteristics of individuals in a bipolar disorder case registry.</ArticleTitle><Pagination><MedlinePgn>120-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The goal of this analysis was to characterize a cohort of 3000 persons who self-identified as having bipolar disorder by demographic, clinical, and treatment characteristics and to document the burden that this disorder imposed on their lives.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Stanley Center Bipolar Disorder Registry used a variety of recruitment methods to reach people with bipolar disorder. The cohort included those currently in treatment and those active in support groups. Registrants completed an interviewer-administered questionnaire to obtain information on demographic characteristics, clinical history, and treatment history.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the 2839 patients who were analyzed was 40.1 years, 64.5% were women, and over 90% were white. The median age at onset was 17.5 years, and the mean was 19.8 years. Despite the fact that over 60% completed at least some college and 30% completed college, 64% were currently unemployed. The patients' family histories point to a high prevalence of mental disorder in the families, especially mood disorders. Patients were concurrently taking multiple medications, and more than one third were taking at least 3 types of psychotropic medications. This pattern of pharmacotherapy was consistent with participants' overall mood ratings, which demonstrated how unusual it was for them to be symptom-free over a 6-month period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our present findings point to the chronicity and severity of bipolar disorder as experienced in the community. We still need to develop better interventions, ensure access to care consistent with current consensus guidelines, and initiate care as early as possible in the course of the condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213, USA. kupferdj@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grochocinski</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Cluss</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Stapf</LastName><ForeName>Debra A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 2002 Nov;63(11):1045-6; author reply 1046</RefSource><PMID Version="1">12469687</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010414" MajorTopicYN="N" Type="Geographic">Pennsylvania</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="N">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014478" MajorTopicYN="N">Unemployment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>9</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11874212</ArticleId><ArticleId IdType="doi">10.4088/jcp.v63n0206</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31081573</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>11</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The Global Aging &amp; Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) project: Understanding older-age bipolar disorder by combining multiple datasets.</ArticleTitle><Pagination><MedlinePgn>642-649</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12795</ELocationID><Abstract><AbstractText Label="OBJECTIVE">There is a dearth of research about the aging process among individuals with bipolar disorder (BD). One potential strategy to overcome the challenge of interpreting findings from existing limited older-age bipolar disorder (OABD) research studies is to pool or integrate data, taking advantage of potential overlap or similarities in assessment methods and harmonizing or cross-walking measurements where different measurement tools are used to evaluate overlapping construct domains. This report describes the methods and initial start-up activities of a first-ever initiative to create an integrated OABD-focused database, the Global Aging &amp; Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) project.</AbstractText><AbstractText Label="METHODS">Building on preliminary work conducted by members of the International Society for Bipolar Disorders OABD taskforce, the GAGE-BD project will be operationalized in four stages intended to ready the dataset for hypothesis-driven analyses, establish a consortium of investigators to guide exploration, and set the stage for prospective investigation using a common dataset that will facilitate a high degree of generalizability.</AbstractText><AbstractText Label="RESULTS">Initial efforts in GAGE-BD have brought together 14 international investigators representing a broad geographic distribution and data on over 1,000 OABD. Start-up efforts include communication and guidance on meeting regulatory requirements, establishing a Steering Committee to guide an incremental analysis strategy, and learning from existing multisite data collaborations and other support resources.</AbstractText><AbstractText Label="DISCUSSION">The GAGE-BD project aims to advance understanding of associations between age, BD symptoms, medical burden, cognition and functioning across the life span and set the stage for future prospective research that can advance the understanding of OABD.</AbstractText><CopyrightInformation>© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3073-668X</Identifier><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eyler</LastName><ForeName>Lisa T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, San Diego, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Desert-Pacific Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rej</LastName><ForeName>Soham</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3908-9124</Identifier><AffiliationInfo><Affiliation>Lady Davis Insitute, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Osvaldo P</ForeName><Initials>OP</Initials><Identifier Source="ORCID">0000-0002-8689-6199</Identifier><AffiliationInfo><Affiliation>Medical School, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumberg</LastName><ForeName>Hilary P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forester</LastName><ForeName>Brent P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>McLean Hospital, Belmont, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forlenza</LastName><ForeName>Orestes V</ForeName><Initials>OV</Initials><Identifier Source="ORCID">0000-0002-6962-5899</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuroscience (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gildengers</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9216-988X</Identifier><AffiliationInfo><Affiliation>Ariel Gildengers, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0002-0303-6450</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Addiction &amp; Mental Health, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8410-7187</Identifier><AffiliationInfo><Affiliation>AREA, Assistance and Research in Affective Disorders, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shangying</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5662-0055</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0548-0053</Identifier><AffiliationInfo><Affiliation>Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine and New York-Presbyterian Hospital, White Plains, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols</LastName><ForeName>Annemiek</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1964-0318</Identifier><AffiliationInfo><Affiliation>GGZ inGeest, Amsterdam UMC, location VU Medical Center, Amsterdam Neuroscience, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="Y">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">elderly</Keyword><Keyword MajorTopicYN="Y">geriatric</Keyword><Keyword MajorTopicYN="Y">manic-depressive disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31081573</ArticleId><ArticleId IdType="doi">10.1111/bdi.12795</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kessing LV, Andersen PK. Evidence for clinical progression of unipolar and bipolar disorders. Acta Psychiatr Scand. 2017;135:51-64.</Citation></Reference><Reference><Citation>Nivoli A, Murru A, Pacchiarotti I, et al. Bipolar disorder in the elderly: a cohort study comparing older and younger patients. Acta Psychiatr Scand. 2014;130:364-373.</Citation></Reference><Reference><Citation>Kessing LV. Diagnostic subtypes of bipolar disorder in older versus younger adults. Bipolar Disord. 2006;8:56-64.</Citation></Reference><Reference><Citation>Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17:689-704.</Citation></Reference><Reference><Citation>Sit D. Women and bipolar disorder across the life span. J Am Med Womens Assoc. 1972;2004(59):91-100.</Citation></Reference><Reference><Citation>Eid L, Heim K, Doucette S, McCloskey S, Duffy A, Grof P. Bipolar disorder and socioeconomic status: what is the nature of this relationship? Int J Bipolar Disord. 2013;1:9.</Citation></Reference><Reference><Citation>Gildengers A, Tatsuoka C, Bialko C, et al. Correlates of disability in depressed older adults with bipolar disorder. Cut Edge Psychiatry Pract. 2013;2013:332-338.</Citation></Reference><Reference><Citation>Dols A, Korten N, Comijs H, et al. The clinical course of late-life bipolar disorder, looking back and forward. Bipolar Disord 2017. https://doi.org/10.1111/bdi.12586. [Epub ahead of print].</Citation></Reference><Reference><Citation>Westman J, Hällgren J, Wahlbeck K, Erlinge D, Alfredsson L, Osby U. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;18(3):e002373. https://doi.org/10.1136/bmjopen-2012-002373.</Citation></Reference><Reference><Citation>Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiatry Rep. 2014;16:499. https://doi.org/10.1007/s11920-014-0499-z.</Citation></Reference><Reference><Citation>Rej S, Quayle W, Forester BP, et al. Measurement tools for assessment of older age bipolar disorder: a systematic review of the recent global literature. Bipolar Disord. 2018;20:359-369. https://doi.org/10.1111/bdi.12566. Epub 2018.</Citation></Reference><Reference><Citation>Sajatovic M, Tatsuoka C, Cassidy KA, et al. A 6-month, prospective, randomized controlled trial of customized adherence enhancement vs. bipolar-specific education control in poorly-adherent individuals with bipolar disorder. J Clin Psychiatry. 2018;79:17m12036. https://doi.org/10.4088/JCP.17m12036.</Citation></Reference><Reference><Citation>Young R, Mulsant B, Sajatovic M, et al. Geri-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017;174:1086-1093. https://doi.org/10.1176/appi.ajp.2017.</Citation></Reference><Reference><Citation>Eyler L, Aebi ME, Daly RE, et al. Understand aging in bipolar disorder by integrating archival clinical research datasets: findings from the Aging and Geriatric Experiments in Bipolar Disorder (AGE-BD) project. Under review.</Citation></Reference><Reference><Citation>LaFrance WC, Ranieri R, Bamps Y, et al. Comparison of common data elements from the Managing Epilepsy Well (MEW) network integrated database and a well-characterized sample with nonepileptic seizures. Epilepsy Behav. 2015;45:136-141.</Citation></Reference><Reference><Citation>Sahoo SS, Zhang G-Q, Bamps Y, et al. Managing information well: toward an ontology-driven informatics platform for data sharing and secondary use in epilepsy self-management research centers. Health Informatics J. 2016;22:548-561.</Citation></Reference><Reference><Citation>Ramesh P, Wei A, Welter E, et al. semantic provenance and analysis platform for multi-center neurology healthcare research. Proc (IEEE Int Conf Bioinformatics Biomed). 2015;731-736.</Citation></Reference><Reference><Citation>Chen E, Sajatovic M, Liu H, et al. Demographic and clinical correlates of seizure frequency: findings from the Managing Epilepsy Well Network Database. J Clin Neurol. 2018;14:206-211.</Citation></Reference><Reference><Citation>Sajatovic M, Jobst BC, Shegog R, et al. The Managing Epilepsy Well Network: advancing Epilepsy Self-Management. Am J Prev Med. 2017a;52:S241-S245.</Citation></Reference><Reference><Citation>Sajatovic M, Tatsuoka C, Welter E, et al. Correlates of quality of life among individuals with epilepsy enrolled in self-management research: from the US Centers for Disease Control and Prevention Managing Epilepsy Well Network. Epilepsy Behav. 2017b;69:177-180.</Citation></Reference><Reference><Citation>Burdick KE, Millett C, del Mar Bonnín C, et al. International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC-BD). Bipolar Disord. 2019;21(1):6-10.</Citation></Reference><Reference><Citation>Shulman KI, Almeida OP, Herrmann N, et al. Adults with Bipolar Disorder Task Force. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD Task Force Report. Bipolar Disord 2018. https://doi.org/10.1111/bdi.12714. Oct 30. [Epub ahead of print].</Citation></Reference><Reference><Citation>Science Gateways Community Institute. https://sciencegateways.org/. Accessed January 11, 2019.</Citation></Reference><Reference><Citation>Australian Genetics of Bipolar Disorder Study. https://www.geneticsofbipolar.org.au/. Accessed January 11, 2019.</Citation></Reference><Reference><Citation>The YODA Project. http://yoda.yale.edu/. Accessed January 11, 2019.</Citation></Reference><Reference><Citation>Enigma. Enigma Bipolar. http://enigma.ini.usc.edu/ongoing/enigma-bipolar-working-group/. Accessed January 11, 2019.</Citation></Reference><Reference><Citation>ConLiGen The International Consortium on Lithium Genetics. http://www.conligen.org/. Accessed January 11, 2019.</Citation></Reference><Reference><Citation>Ross JS, Waldstreicher J, Bamford S, et al. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Sci Data. 2018;5:180268.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21981895</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2011</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Management, needs and expectations of patients suffering from bipolar I disorders (The ECHO study - France)].</ArticleTitle><Pagination><MedlinePgn>332-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2011.07.006</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The ECHO study is the first French study directly asking patients with bipolar I disorders on the history and experiences of their disease, their perceptions of care, their sociofamilial relationships, and their expectations regarding what should be done by healthcare professionals and their environment.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Three hundred euthymic patients suffering from bipolar disorder I were interviewed using a semi-standardized evaluation through telephone interviews. These patients were selected according to the quota method of nationally representative INSEE 99 to be representative of the French population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-nine percent of patients consulted at least once for psychological signs before the correct diagnosis was established. The average age at the time of diagnosis was of 30.1 years (± 11.3). The average time between first consultation for psychological symptoms and diagnosis is about 5 years. In 92% of cases, the psychiatrist is the health professional that made the diagnosis; 74% of patients were also followed by a general practitioner. One hundred percent of participants had been hospitalized for manic episodes (criterion for inclusion in the study) and 86% were also hospitalized for depressive symptoms. The experience of hospitalization is positive (feeling of security for 84% of the sample, feelings of being helped for 81% of the sample), although these experiences are also associated with the perception of confinement (52% of the sample). At the time of the interview, 97% of these patients were followed by one or more health professionals. Only 34% of these patients were taking a mood stabilizer (lithium, anticonvulsant or atypical antipsychotic with indications in France for bipolar disorder), while 44% were taking an antidepressant and 38% were taking anxiolytics; 84% of patients had experienced side effects related to their current treatment. Acceptance of the disease is difficult and only 56% of patients personally feel they suffer from bipolar disorders. Patients believe that their mental health problems have a significant impact on their lives, including impact on their self-esteem and happiness. Relationships with family, friends but also sexual relations are affected. Even in the euthymic phase, 44% of patients have difficulties in their daily tasks. Three quarters of patients said they had already experienced rejection or discrimination related to their disease. Finally, patients gave a score of 6.4 out of 10 to assess the impact of the disorder on their quality of life. Patients request more dialogue with health professionals and a more personalized treatment, taking into account side effects. They also want more information on the treatment. They would also like to be supported, together with their families, and advised on how to cope with the disease.</AbstractText><CopyrightInformation>Copyright © 2011 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guillaume</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm, U1061, 34093 Montpellier, France. s-guillaume@chu-montpellier.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courtet</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chabannes</LastName><ForeName>J-P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Meynard</LastName><ForeName>J-A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Moreau-Mallet</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prises en charge, besoins et attentes de patients souffrant de troubles bipolaires I (Étude ECHO - France).</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006301" MajorTopicYN="Y">Health Services Needs and Demand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="N">Patient Preference</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011287" MajorTopicYN="N">Prejudice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21981895</ArticleId><ArticleId IdType="pii">S0013-7006(11)00141-2</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2011.07.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17391822</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2007</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>952-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We investigated the association between serum levels of C-reactive protein (CRP), a marker of inflammation, and the severity of psychopathology in outpatients with bipolar disorder. We also compared the levels of CRP in the bipolar disorder individuals with those of a non-psychiatric control group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We measured the level of CRP in N=122 outpatients with bipolar disorder and N=165 control individuals and evaluated the symptom severity of the bipolar disorder patients with the Young Mania Rating Scale (YMRS) and the Hamilton Depression Scale (Ham-D).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within the bipolar disorder sample, CRP was significantly associated with the YMRS score (r=.306, p&lt;.006), age of onset, gender, and race. CRP was not significantly associated with the Ham-D score or other clinical or demographic variables. In a multivariate analysis of covariance, CRP was the only independent predictor of YMRS score (F=11.7, p=.0009). The CRP levels of the n=41 individuals with YMRS &gt;6 were significantly greater than the levels of the n=81 individuals with YMRS &lt;or=6 (F=7.94, &lt;.006). The CRP levels of the group with YMRS &gt;6 were also significantly greater than the levels of the control group (p=.033) while the CRP levels of the group with YMRS &lt;or=6 did not differ from that of controls (p&gt;.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that outpatients with bipolar disorder with mania symptoms have increased levels of CRP as compared to those without mania symptoms and compared to individuals without psychiatric disorders. The long-term consequences of CRP in bipolar disorder should be the subject of future studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Faith</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Stanley Research Center at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD 21204, USA. fdickerson@sheppardpratt.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stallings</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Origoni</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Boronow</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yolken</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="Y">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>01</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17391822</ArticleId><ArticleId IdType="pii">S0278-5846(07)00077-2</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2007.02.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18533757</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69 Suppl 3</Volume><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Optimizing treatment outcomes in bipolar disorder under ordinary conditions.</ArticleTitle><Pagination><MedlinePgn>11-9</MedlinePgn></Pagination><Abstract><AbstractText>The gold standard for establishing the efficacy of a drug is the randomized controlled trial (RCT). In the past decade, there has been an increasing recognition of the important difference between RCTs designed to demonstrate efficacy and treatment studies designed to evaluate the effectiveness of various therapies in actual clinical practice. This distinction is especially true for bipolar disorder, a complex illness whose treatment response is significantly influenced by various moderating baseline factors (e.g., comorbidity, severity, treatment resistance) and mediating factors (e.g., adequacy of dose and treatment duration, use of concomitant medications, treatment adherence). To reduce sources of variance in treatment outcome, RCTs rely on restrictive entry criteria in an attempt to control moderating factors and on highly standardized study procedures in an attempt to control mediating factors. The goal is to reduce the heterogeneity in the patient sample and in treatments administered and thereby to increase the internal validity of the study. Unfortunately, the results of rigorously controlled RCTs with strong internal validity are often not highly generalizable to the real-world setting of actual clinical practice. The aim of this paper is to briefly review key variables that influence treatment outcome of bipolar disorder in real-world clinical settings and to discuss strategies for optimizing treatment outcomes under ordinary conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA. JFGoldberg@yahoo.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>85</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18533757</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16203954</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon.</ArticleTitle><Pagination><MedlinePgn>1089-96</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The prevalence of depressive symptoms co-occurring with hypomanic symptoms has not been quantified. Whether there is a greater likelihood for women to experience mixed symptoms has not been resolved.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether mixed hypomania is observed more frequently than euphoric hypomania and whether a sex effect exists in patients with bipolar disorder.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic research settings in the United States (4 sites) and Europe (3 sites).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Subjects were enrolled in a naturalistic prospective study after providing written informed consent.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Mixed hypomania was defined at a given visit as a Young Mania Rating Scale score of 12 or higher and an Inventory of Depressive Symptomatology-Clinician-Rated Version score of 15 or higher. Given partial overlap of items from these scales, exploratory analyses were completed assessing instrument overlap affecting the findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 908 patients, 14 328 visits over 7 years were evaluated. Patients with bipolar I disorder were significantly more likely to experience hypomania than those with bipolar II disorder. Of all 1044 visits by patients with hypomanic symptoms, 57% met criteria for mixed hypomania. The likelihood of depression was significantly greater for women during hypomania (P&lt;.001). For women, the probability of mixed symptoms increased with the severity of hypomania and then decreased at the most severe levels of hypomania or mania. When a modified Inventory of Depressive Symptomatology-Clinician-Rated Version was evaluated by removing the 5 overlapping Young Mania Rating Scale items, a significant sex effect persisted for women (P&lt;.001) but not for men (P = .95), owing to the elimination of the items "irritability" and "agitation."</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mixed hypomania is common in patients with symptoms of hypomania and particularly common in women. Potential overlap of clinical symptom scales should be assessed before study of patients with bipolar disorder symptoms is undertaken.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Research Program, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75390-9121, USA. trisha.suppes@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>A John</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH079261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16203954</ArticleId><ArticleId IdType="pii">62/10/1089</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.62.10.1089</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22108181</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4 Suppl 4</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Agitated states in adolescence].</ArticleTitle><Pagination><MedlinePgn>H8-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(11)70026-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braconnier</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre Psychiatrique et Psychothérapique Philippe Paumelle, 11 rue Albert Bayet, Paris, France. alain.braconnier@asm13.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les états d'agitation à l'adolescence.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22108181</ArticleId><ArticleId IdType="pii">S0013-7006(11)70026-4</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(11)70026-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19886294</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1461-7285</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6 Suppl</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Metabolic and lifestyle issues and severe mental illness--new connections to well-being?</ArticleTitle><Pagination><MedlinePgn>188-22</MedlinePgn></Pagination><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006694" MajorTopicYN="N">Holistic Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010809" MajorTopicYN="Y">Physical Fitness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>0</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19886294</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9004061</PMID><DateCompleted><Year>1997</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>1997</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Induction of mania by risperidone resistant to mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>57-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barkin</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Pais</LastName><ForeName>V M</ForeName><Initials>VM</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Gaffney</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9004061</ArticleId><ArticleId IdType="doi">10.1097/00004714-199702000-00013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21176024</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Striatal structure and function in mood disorders: a comprehensive review.</ArticleTitle><Pagination><MedlinePgn>764-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2010.00874.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">  A large and diverse literature has implicated abnormalities of striatal structure and function in both unipolar and bipolar disorder. Recent functional imaging studies have greatly expanded this body of research. The aim of this review is to provide a comprehensive and critical appraisal of the relevant literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">  A total of 331 relevant articles were reviewed to develop an integrated overview of striatal function in mood disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">  There is compelling evidence from multiple studies that functional abnormalities of the striatum and greater corticostriatal circuitry exist in at least some forms of affective illness. The literature does not yet provide data to determine whether these aberrations represent primary pathology or they contribute directly to symptom expression. Finally, there is considerable evidence that bipolar disorder may be associated with striatal hyperactivity and some suggestion that unipolar illness may be associated with hypoactivation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">  Additional research investigating striatal function in affective disorders will be critical to the development of comprehensive models of the neurobiology of these conditions.</AbstractText><CopyrightInformation>© 2010 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marchand</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, VISN 19 MIRECC, 5500 Foothill, Salt Lake City, UT 84148, USA. wmarchand@me.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurgelun-Todd</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21176024</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2010.00874.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9766693</PMID><DateCompleted><Year>1998</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The increasing use of anticonvulsants in prophylactic treatment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>429-31</MedlinePgn></Pagination><Abstract><AbstractText>The medical records of patents with bipolar disorders who received prophylactic drug treatments during three time periods from January 1983 to December 1984, January 1988 to December 1989, and from January 1993 to December 1994, were reviewed retrospectively. The percentage of lithium monotherapy sharply decreased from 96% (51/53) in the first study period to 51.9% (83/160) in the third study period. Carbamazepine monotherapy and combination of lithium and carbamazepine increased from 3.8% in the first study period to 45.6% in the third study period. These results suggest that anticonvulsants may become one of the major drug treatment strategies for bipolar disorder in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Y Y</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Chang Gung College of Medicine and Technology, and Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9766693</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1819.1998.00405.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9111853</PMID><DateCompleted><Year>1997</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>95</Volume><Issue>3</Issue><PubDate><Year>1997</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Prediction of depressive relapse in remitted bipolar patients using corticotrophin-releasing hormone challenge test.</ArticleTitle><Pagination><MedlinePgn>205-11</MedlinePgn></Pagination><Abstract><AbstractText>Abnormalities in corticotrophin (ACTH) and cortisol levels before and after corticotrophin-releasing hormone (CRH) stimulation have been reported in depressed bipolar patients. The ACTH and free cortisol response to the injection of 100 micrograms of synthetic human CRH and plasma cortisol-binding globulin (CBG) levels were measured in 42 lithium-treated patients suffering from RDC bipolar-I disorder in remission, and in 21 age- and sex-matched control subjects. A 1-year follow-up was conducted in order to assess any possible relationship between outcome and the hormonal response. Bipolar patients showed higher baseline and peak ACTH concentrations than controls. A lower net area under the ACTH concentration curve after CRH stimulation predicted depressive relapse within 6 months by multiple regression analysis. The CRH challenge test could be a potentially good predictor of depressive relapse in remitted bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hormonal Laboratory, University of Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasto</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Martinez de Osaba</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Nieto</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Canto</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Otero</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vallejo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-60-2</RegistryNumber><NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9015-71-8</RegistryNumber><NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003346" MajorTopicYN="Y">Corticotropin-Releasing Hormone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9111853</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1997.tb09621.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33901658</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1220</ISSN><JournalIssue CitedMedium="Internet"><Volume>211</Volume><PubDate><Year>2021</Year><Month>07</Month></PubDate></JournalIssue><Title>The Journal of steroid biochemistry and molecular biology</Title><ISOAbbreviation>J Steroid Biochem Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Plasma oxysterols: Altered level of plasma 24-hydroxycholesterol in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>105902</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0960-0760(21)00095-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsbmb.2021.105902</ELocationID><Abstract><AbstractText>Cholesterol and its oxygenated metabolites, including oxysterols, are intensively investigated as potential players in the pathophysiology of brain disorders. Altered oxysterol levels have been described in patients with numerous neuropsychiatric disorders. Recent studies have shown that Bipolar disorder (BD) is associated with the disruption of cholesterol metabolism. The present study was aimed at investigating the profile of oxysterols in plasma, their ratio to total cholesterol and their association with clinical parameters in patients with BD. Thirty three men diagnosed with BD and forty healthy controls matched for age and sex were included in the study. Oxysterol levels were measured by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Significantly higher levels were observed for cholestane-3β,5α,6β-triol, 27-hydroxycholesterol (27-OHC) and Cholestanol in patients with BD. The concentration of 24-hydroxycholesterol (24-OHC) was significantly lower in patients compared to controls. 24-OHC was also negatively correlated to MAS subscale score (r =-0.343; p = 0.049). In patients, 24-OHC was inversely correlated with age (r = -0.240; p = 0.045). Multivariate analysis found that BD acute decompensation was independently related to the rise in plasma 24-OHC (p = 0.002; OR = 0.966, 95 % CI [0.945 - 0.987]). However, the 24-OHC assay relevance as a biomarker of this disease deserves further investigation in other studies.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guidara</LastName><ForeName>Wassim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Research "Molecular Basis of Human Diseases", LR19ES13, Faculty of Medicine, University of Sfax, Sfax, Tunisia. Electronic address: wassimguidara44@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messedi</LastName><ForeName>Meriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Research "Molecular Basis of Human Diseases", LR19ES13, Faculty of Medicine, University of Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maalej</LastName><ForeName>Manel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry C-department, University of Sfax &amp; Hédi Chaker Hospital, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naifar</LastName><ForeName>Manel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Research "Molecular Basis of Human Diseases", LR19ES13, Faculty of Medicine, University of Sfax, Sfax, Tunisia; Laboratory of Biochemistry, University of Sfax &amp; Habib Bourguiba Hospital, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khrouf</LastName><ForeName>Walid</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>AP-HP, Sorbonne University, La Pitié-Salpêtrière University Hospital, Department of Metabolic Biochemistry, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grayaa</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Research "Molecular Basis of Human Diseases", LR19ES13, Faculty of Medicine, University of Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maalej</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry C-department, University of Sfax &amp; Hédi Chaker Hospital, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnefont-Rousselot</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>AP-HP, Sorbonne University, La Pitié-Salpêtrière University Hospital, Department of Metabolic Biochemistry, Paris, France; UTCBS, U1267 Inserm, UMR 8258 CNRS, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamari</LastName><ForeName>Foudil</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AP-HP, Sorbonne University, La Pitié-Salpêtrière University Hospital, Department of Metabolic Biochemistry, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayadi</LastName><ForeName>Fatma</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Research "Molecular Basis of Human Diseases", LR19ES13, Faculty of Medicine, University of Sfax, Sfax, Tunisia; Laboratory of Biochemistry, University of Sfax &amp; Habib Bourguiba Hospital, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Steroid Biochem Mol Biol</MedlineTA><NlmUniqueID>9015483</NlmUniqueID><ISSNLinking>0960-0760</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006888">Hydroxycholesterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>47IMW63S3F</RegistryNumber><NameOfSubstance UI="C044563">24-hydroxycholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006888" MajorTopicYN="N">Hydroxycholesterols</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014416" MajorTopicYN="N" Type="Geographic">Tunisia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">24-hydroxycholesterol</Keyword><Keyword MajorTopicYN="Y">27-hydroxycholesterol</Keyword><Keyword MajorTopicYN="Y">Biomarker</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Oxysterols</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>26</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33901658</ArticleId><ArticleId IdType="pii">S0960-0760(21)00095-9</ArticleId><ArticleId IdType="doi">10.1016/j.jsbmb.2021.105902</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24709019</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>More pernicious course of bipolar disorder in the United States than in many European countries: implications for policy and treatment.</ArticleTitle><Pagination><MedlinePgn>27-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.02.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00037-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is some controversy but growing evidence that childhood onset bipolar disorder may be more prevalent and run a more difficult course in the United States than some European countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We update and synthesize course of illness data from more than 960 outpatients with bipolar disorder (average age 40) from 4 sites in the U.S. and 3 sites in Netherlands and Germany. After giving informed consent, patients reported on parental history, childhood and lifetime stressors, comorbidities, and illness characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Almost all aspects of bipolar disorder were more adverse in patients from the US compared with Europe, including a significantly higher prevalence of: bipolar disorder in one parent and a mood disorder in both parents; childhood verbal, physical, or sexual abuse; stressors in the year prior to illness onset and the last episode; childhood onsets of bipolar illness; delay to first treatment; anxiety disorder, substance abuse, and medical comorbidity; mood episodes and rapid cycling; and nonresponse to prospective naturalistic treatment.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Selection bias in the recruit of patients cannot be ruled out, but convergent data in the literature suggest that this does not account for the findings. Potential mechanisms for the early onset and more adverse course in the U.S. have not been adequately delineated and require further investigation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data suggest the need for earlier and more effective long-term treatment intervention in an attempt to ameliorate this adverse course and its associated heavy burden of psychiatric and medical morbidity.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Bipolar Collaborative Network, 5415 W. Cedar Ln, Suite 201-B, Bethesda, MD 20814, United States; Psychiatry and Behavioral Sciences, George Washington University, Washington, D.C., United States. Electronic address: Robert.post@speakeasy.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UCLA Mood Disorders Research Program, VA Medical Center, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, VU University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lindner Center of HOPE Mason, OH, United States; Biological Psychiatry Program, University of Cincinnati Medical College, Cincinnati, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Psychiatry, Mayo Clinic, Rochester, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistician, Bipolar Collaborative Network, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>G S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Bipolar Collaborative Network, 5415 W. Cedar Ln, Suite 201-B, Bethesda, MD 20814, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, University of Newcastle upon Tyne, Newcastle, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Psychiatry and Behavioral Sciences, Stanford University School of Medicine, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>P E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Psychiatry &amp; Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States; Lindner Center of HOPE Mason, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>University Medical Center, University of Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Early onset</Keyword><Keyword MajorTopicYN="N">Epigenetics</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Rapid cycling</Keyword><Keyword MajorTopicYN="N">Stress</Keyword><Keyword MajorTopicYN="N">Substance abuse disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24709019</ArticleId><ArticleId IdType="pii">S0165-0327(14)00037-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.02.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19602917</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2009</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0348</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>5</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Psychotherapy and psychosomatics</Title><ISOAbbreviation>Psychother Psychosom</ISOAbbreviation></Journal><ArticleTitle>Functioning and disability in bipolar disorder: an extensive review.</ArticleTitle><Pagination><MedlinePgn>285-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000228249</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder has generally been regarded as having a better functional outcome than schizophrenia. However, studies have suggested low functioning in bipolar patients even when they are in clinical remission. Our aim was to determine the degree of functioning and disability in bipolar patients. Secondly, we reviewed factors potentially associated with the low functioning of bipolar patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors conducted an extensive Medline and Pubmed search of the published literature from 1980 up to December 2007, using a variety of search terms to find relevant articles. Bibliographies of retrieved papers were further analysed for publications of interest. Articles that reported clinically significant findings on functioning and disability, and research reports were reviewed in detail.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From these articles, we determined that bipolar disorder is associated with significant impairment in work, family and social life, beyond the acute phases of the illness. The aspects that appear to increase the risk of low functioning and disability in bipolar patients are mainly subsyndromal symptoms and neurocognitive impairment, among others.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Suitable pharmacological and psychological interventions may improve the level of functioning and reduce the disability in bipolar patients. Potential targets to be considered for intervention should be residual symptoms, comorbid conditions and neurocognitive deficits. Further research is required to better identify the factors that best predict functioning in bipolar patients.</AbstractText><CopyrightInformation>Copyright 2009 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Moreno</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Institute of Neuroscience, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Aran</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tabarés-Seisdedos</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ayuso-Mateos</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychother Psychosom</MedlineTA><NlmUniqueID>0024046</NlmUniqueID><ISSNLinking>0033-3190</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005195" MajorTopicYN="N">Family Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>148</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19602917</ArticleId><ArticleId IdType="pii">000228249</ArticleId><ArticleId IdType="doi">10.1159/000228249</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16480418</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-5990</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Perspectives in psychiatric care</Title><ISOAbbreviation>Perspect Psychiatr Care</ISOAbbreviation></Journal><ArticleTitle>Treatment considerations for patients experiencing rapid-cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>55-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antai-Otong</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>deborah-antai-otong@med.va.gov</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Perspect Psychiatr Care</MedlineTA><NlmUniqueID>0401133</NlmUniqueID><ISSNLinking>0031-5990</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009730" MajorTopicYN="N">Nursing Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="Y">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011568" MajorTopicYN="N">Psychiatric Nursing</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16480418</ArticleId><ArticleId IdType="pii">PPC049</ArticleId><ArticleId IdType="doi">10.1111/j.1744-6163.2006.00049.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2689436</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>50 Suppl</Volume><PubDate><Year>1989</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The biology of recurrence: new directions for the pharmacologic bridge.</ArticleTitle><Pagination><MedlinePgn>40-4; discussion 45-7</MedlinePgn></Pagination><Abstract><AbstractText>Recurrence is a fundamental reality of the major affective disorders and must be considered in treatment planning. Historically, however, information regarding the pathophysiology and neurobiology of affective disorders was not gained from studies on recurrence, but rather from research utilizing drugs classified on the basis of their effect on acute manic and/or depressive states. Though such cross-sectional strategies were critical in developing the original amine hypotheses, they also were inherently limited. Today, accumulating information regarding differential drug effects on cycle length calls for reexamining the pharmacologic bridge from the perspective of the nascent neurobiology of recurrence of affective disorders. This presentation considers the array of drugs now used in treating mood disorders and reviews recent data relating to the role of acute and maintenance treatments on the occurrence of manic and hypomanic reactions in bipolar patients. In addition, emerging data on the impact of longitudinal treatments on the natural course of bipolar illness are used to develop a model for examining the effects of treatment on recurring unipolar illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>F K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Md. 20857.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="N">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>31</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2689436</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2142702</PMID><DateCompleted><Year>1990</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>1990</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Four-year follow-up of twenty-four first-episode manic patients.</ArticleTitle><Pagination><MedlinePgn>79-86</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-four first-episode manic patients were followed to investigate the 4-year outcome after recovery from a manic episode. Patients had no documented previous manic or depressive episodes. The presence of psychotic features during the index episode and a history of alcoholism were statistically significant predictors of a shorter time in remission. Low occupational status at baseline predicted poor global social adjustment at 4 years. Also, a larger correlation among outcome measures was found at 48 than at 6 months. The importance of controlling for presence of multiple episodes in outcome studies is emphasized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard School of Medicine, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waternaux</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>A T</ForeName><Initials>AT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2142702</ArticleId><ArticleId IdType="pii">0165-0327(90)90012-W</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(90)90012-w</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23036958</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Abnormal temporal lobe white matter as a biomarker for genetic risk of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>177-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2012.07.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(12)00692-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain white matter (WM) abnormalities have been hypothesized to play an important role in the neurobiology of bipolar disorder (BD). The nature of these abnormalities is not well-characterized, however, and it is unknown whether they occur after disease onset or represent potential markers of genetic risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined WM integrity (assessed via fractional anisotropy [FA]) with diffusion tensor imaging in patients with BD (n=26), unaffected siblings of patients with BD (n=15), and healthy volunteers (n=27) to identify WM biomarkers of genetic risk.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The FA differed significantly (p&lt;.05; corrected) among the three groups within the right temporal WM. Unaffected siblings had FA values that were intermediate to and significantly different from those of healthy volunteers and patients with BD (healthy control subjects&gt;unaffected siblings&gt;BD). Moreover, FA values in this region correlated negatively and significantly with trait impulsivity in unaffected siblings. Probabilistic tractography indicated that the regional abnormality lies along the inferior fronto-occipital fasciculus, a large intrahemispheric association pathway.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that lower WM integrity in the right temporal lobe might be a biomarker for genetic risk of BD. It is conceivable that the attenuated nature of these WM abnormalities present in unaffected siblings allows for some preservation of adaptive emotional regulation, whereas more pronounced alterations observed in patients is related to the marked emotional dysregulation characteristic of BD.</AbstractText><CopyrightInformation>Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahon</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1230, New York, NY 10029, USA. katie.mahon@mssm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burdick</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Ikuta</LastName><ForeName>Toshikazu</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Braga</LastName><ForeName>Raphael J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Gruner</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Anil K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Szeszko</LastName><ForeName>Philip R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01 RR018535</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076995</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH080173</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH062994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH077807</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biol Psychiatry. 2013 Jan 15;73(2):109-10</RefSource><PMID Version="1">23245951</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="Y">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="N">Siblings</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23036958</ArticleId><ArticleId IdType="pii">S0006-3223(12)00692-0</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2012.07.033</ArticleId><ArticleId IdType="pmc">PMC3760506</ArticleId><ArticleId IdType="mid">NIHMS496146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 1973 Jan;122(566):15-30</Citation><ArticleIdList><ArticleId IdType="pubmed">4683020</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 May;160(5):999-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">12727708</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2004 Jan;230(1):77-87</Citation><ArticleIdList><ArticleId IdType="pubmed">14645885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1041-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18762590</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Jan 1;34(1):144-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17070705</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Nov 1;54(9):896-905</Citation><ArticleIdList><ArticleId IdType="pubmed">14573317</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2006 Apr;11(4):269-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16641833</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):316-28</Citation><ArticleIdList><ArticleId IdType="pubmed">19255710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Jun;10(4):460-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18452442</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Jan;45(1):76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20488462</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2005 Apr 29;360(1456):767-79</Citation><ArticleIdList><ArticleId IdType="pubmed">15937011</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Oct;161(10):1814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15465978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Oct 1;42(4):1654-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18620064</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Aug 1;50(3):184-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11513817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2010 Jan;20(1):121-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19406904</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 May;33(5):699-771</Citation><ArticleIdList><ArticleId IdType="pubmed">19428491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Apr;17(4):412-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21321565</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2003 Sep;126(Pt 9):2093-107</Citation><ArticleIdList><ArticleId IdType="pubmed">12821517</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Jan 1;44(1):83-98</Citation><ArticleIdList><ArticleId IdType="pubmed">18501637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2002 Mar;3(3):201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Aug 1;66(3):238-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19389661</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortex. 2010 May;46(5):691-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19775684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2010 May;117(5):639-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20107844</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 Mar;34(4):533-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19896972</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Feb;66(2):142-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19188536</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jun;194(6):527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19478293</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2003 Nov;153(2):146-57</Citation><ArticleIdList><ArticleId IdType="pubmed">14610633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17328959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 15;31(4):1487-505</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Sep 24;28(39):9790-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18815263</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Med Res. 2006 Jan;37(1):79-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16314191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">18076529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):171-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15117396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):280-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19419385</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Nov;118(5):357-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18644004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anat. 2011 Oct;219(4):531-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21767263</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 1995 Nov;51(6):768-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8778124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1249-59, 1259.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">21093774</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1050-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19500633</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Aug 15;70(4):350-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21429475</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Oct;61(10):974-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15466670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30336492</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0224</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>1</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis.</ArticleTitle><Pagination><MedlinePgn>49-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000493740</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of this study was to evaluate serum levels of the antineuronal antibodies anti-N-methyl-D-aspartate receptor (NMDAR) and anti-glutamic acid decarboxylase (GAD), and insulin-like growth factor 1 (IGF-1), in patients with bipolar disorder (BD), during manic and depressive episodes and in remission compared to euthymic patients receiving long-term lithium therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum levels of anti-NMDAR and anti-GAD 450/620 antibodies, as well as IGF-1, were measured using the ELISA method in 19 manic and 17 depressed patients both in an acute episode and in remission after the episode. All of the subjects were under pharmacological treatment. The control group included 18 euthymic BD patients receiving lithium for 9-44 years (mean 22 ± 11) in whom a single measurement was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum levels of anti-NMDAR antibodies were higher in acute manic episodes than in lithium-treated patients. Serum levels of anti-GAD 450/620 antibodies were higher in acute manic and depressive episodes compared to remission after the respective episode. Their values in both acute manic and depressive episodes were higher than those in lithium-treated patients. Serum levels of IGF-1 were higher in acute manic episodes and in remission after mania than in lithium-treated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Higher levels of anti-NMDAR and anti-GAD antibodies during episodes may point to an abnormality in the glutamatergic system in BD. Increased levels of IGF-1 during an acute manic episode and in remission after mania may constitute a compensatory mechanism against excitotoxicity. Lower levels of anti-NMDAR, anti-GAD antibodies, and IGF-1 during long-term lithium treatment may reflect normalization of this processes, contributing to mood stabilization.</AbstractText><CopyrightInformation>© 2018 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferensztajn-Rochowiak</LastName><ForeName>Ewa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Polandferensztajnewa@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaczmarek</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wójcicka</LastName><ForeName>Marlena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman-Szukalska</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dziuda</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remlinger-Molenda</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szeliga-Neymann</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losy</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroimmunology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583557">IGF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Glutamic acid decarboxylase antibodies</Keyword><Keyword MajorTopicYN="N">Insulin-like growth factor 1</Keyword><Keyword MajorTopicYN="N">Lithium prophylaxis</Keyword><Keyword MajorTopicYN="N">N-methyl-D-aspartate receptor antibodies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30336492</ArticleId><ArticleId IdType="pii">000493740</ArticleId><ArticleId IdType="doi">10.1159/000493740</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8685296</PMID><DateCompleted><Year>1996</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>1996</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies.</ArticleTitle><Pagination><MedlinePgn>401-10</MedlinePgn></Pagination><Abstract><AbstractText>The dominant, contemporary paradigm for developing and refining diagnoses relies heavily on assessing reliability with kappa coefficients and virtually ignores a core component of psychometric practice: the theory of latent structures. This article describes a psychometric approach to psychiatric nosology that emphasizes the diagnostic accuracy and confusability of diagnostic categories. We apply these methods to the Diagnostic Interview for Genetic Studies (DIGS), a structured psychiatric interview designed by the NIMH Genetics Initiative for genetic studies of schizophrenia and bipolar disorder. Our results show that sensitivity and specificity were excellent for both DSM-III-R and RDC diagnoses of major depression, bipolar disorder, and schizophrenia. In contrast, diagnostic accuracy was substantially lower for subtypes of schizoaffective disorder-especially for the DSM-III-R definitions. Both the bipolar and depressed subtypes of DSM-III-R schizoaffective disorder had excellent specificity but poor sensitivity. The RDC definitions also had excellent specificity but were more sensitive than the DSM-III-R schizoaffective diagnoses. The source of low sensitivity for schizoaffective subtypes differed for the two diagnostic systems. For RDC criteria, the schizoaffective subtypes were frequently confused with one another; they were less frequently confused with other diagnoses. In contrast, the DSM-III-R subtypes were often confused with schizophrenia, but not with each other.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>S V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Harvard Institute of Psychiatric Epidemiology and Genetics, Harvard Medical School Department of Psychiatry, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blehar</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pepple</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Moldin</LastName><ForeName>S O</ForeName><Initials>SO</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nurnberger</LastName><ForeName>J I</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kaufmann</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Cloninger</LastName><ForeName>C R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>DePaulo</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Kirch</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>UO1 MH46274</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 MH46276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 MH46318</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8685296</ArticleId><ArticleId IdType="doi">10.1017/s0033291700034796</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22822175</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4167</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Behavior modification</Title><ISOAbbreviation>Behav Modif</ISOAbbreviation></Journal><ArticleTitle>Transdiagnostic treatment of bipolar disorder and comorbid anxiety with the unified protocol: a clinical replication series.</ArticleTitle><Pagination><MedlinePgn>482-508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0145445512451272</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a chronic, debilitating disorder with recurrent manic and depressive episodes. More than 75% of bipolar patients have a current or lifetime diagnosis of a comorbid anxiety disorder. Comorbid anxiety in BD is associated with greater illness severity, greater functional impairment, and poorer illness-related outcomes. Effectively treating comorbid anxiety in individuals with BD has been recognized as one of the biggest unmet needs in the field of BD. Recently, the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) was developed to be applicable to the full range of anxiety and mood disorders, based on converging evidence from genetics, cognitive and affective neuroscience, and behavioral research suggesting common, core emotion-related pathology. Here, the authors present a preliminary evaluation of the efficacy of the UP for the treatment of BD with comorbid anxiety, in a clinical replication series consisting of three cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellard</LastName><ForeName>Kristen K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital/Harvard Medical School, Boston, USA. kellard@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckersbach</LastName><ForeName>Thilo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>Louisa G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Barlow</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01HS01937101</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01MH090053.</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH098490</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH079157-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K23MH091182-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K23MH074895-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31MH084422</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Behav Modif</MedlineTA><NlmUniqueID>7803043</NlmUniqueID><ISSNLinking>0145-4455</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22822175</ArticleId><ArticleId IdType="pii">0145445512451272</ArticleId><ArticleId IdType="doi">10.1177/0145445512451272</ArticleId><ArticleId IdType="pmc">PMC3913370</ArticleId><ArticleId IdType="mid">NIHMS494826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Feb;68(1):1-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11869778</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2003 Oct;54(10):1395-401</Citation><ArticleIdList><ArticleId IdType="pubmed">14557527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Feb;67(2):277-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16566624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Oct;133(3):371-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21093062</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2011 May;17(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21587004</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Behav Pract. 2010 Feb;17(1):102-113</Citation><ArticleIdList><ArticleId IdType="pubmed">23997572</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2010 Oct;27(10):882-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20886609</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jul;167(7):748-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20595427</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Jul;189:20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16816301</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Jun;6(2):139-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12890307</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2005 May-Jun;13(3):155-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16020028</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Oct;124(4):307-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21644938</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2009;21(4):357-67</Citation><ArticleIdList><ArticleId IdType="pubmed">20374149</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569893</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2012 Sep;43(3):666-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22697453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2007 Sep;13(5):291-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17890977</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 Apr;31(3):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11305854</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2008 Jul;53(7):441-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18674402</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17328959</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2008 Jun;79(2):139-50</Citation><ArticleIdList><ArticleId IdType="pubmed">18491230</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 Mar-Apr;46(2):98-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15723025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2008 Oct 1;32(5):702-713</Citation><ArticleIdList><ArticleId IdType="pubmed">20360996</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Apr;188:313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16582056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2011 Nov;120(4):956-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21553935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Jul;66(7):870-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16013903</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Feb;162(2):324-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15677598</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2007 Sep;38(3):284-302</Citation><ArticleIdList><ArticleId IdType="pubmed">17697853</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17430295</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2007</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The spectrum of substance abuse in bipolar disorder: reasons for use, sensation seeking and substance sensitivity.</ArticleTitle><Pagination><MedlinePgn>213-20</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the spectrum of alcohol and substance abuse, including reasons for use, in patients with bipolar I disorder, compared with patients with substance use disorder and healthy controls, with a specific focus on the relationship between substance use, substance sensitivity, other comorbid psychiatric symptoms and traits related to sensation seeking.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included 104 patients with bipolar I disorder (BPD I), of whom 57 (54.8%) met DSM-IV criteria for lifetime alcohol or substance use disorder (BPD + SUD), 35 patients with substance use disorder (SUD) and no psychiatric disorder and 50 healthy controls. Assessments included the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) and the Structured Clinical Interview for the Spectrum of Substance Use (SCI-SUBS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with BPD + SUD and SUD had significantly higher scores on the SCI-SUBS domains of self-medication, substance sensitivity and sensation seeking compared with patients with BPD and healthy controls. Reasons for substance use did not differ between patients with BPD + SUD and patients with SUD. Those most frequently cited were: improving mood; relieving tension; alleviating boredom; achieving/maintaining euphoria; and increasing energy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Recourse to substances is associated with increased mood and anxiety symptoms, substance sensitivity, and sensation seeking among patients with BPD + SUD and SUD. Substance sensitivity and sensation seeking traits should be investigated in all patients with BPD as possible factors associated with a development of SUD, in order to warn patients of the specific risks related to improper use of medications and substances.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bizzarri</LastName><ForeName>Jacopo V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Drug Addiction Service, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbrana</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rucci</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ravani</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Massei</LastName><ForeName>Guido Jacopo</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Gonnelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Spagnolli</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Doria</LastName><ForeName>Maria Rosa</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Raimondi</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dell'Osso</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Cassano</LastName><ForeName>Giovanni Battista</ForeName><Initials>GB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001887" MajorTopicYN="N">Boredom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012651" MajorTopicYN="N">Self Medication</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17430295</ArticleId><ArticleId IdType="pii">BDI383</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00383.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12128239</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Heterogeneity in EEG sleep findings in adolescent depression: unipolar versus bipolar clinical course.</ArticleTitle><Pagination><MedlinePgn>273-80</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">EEG sleep measures in child and adolescent subjects with depression have shown considerable variability regarding group differences between depressed and control subjects. This investigation was designed to assess whether some of the observed variability is related to undifferentiated unipolar and bipolar disorders in a sample that was reported previously.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-eight adolescents who met criteria for unipolar major depression and 35 controls with no lifetime psychiatric disorder participated in a cross-sectional sleep polysomnography study. Approximately 7 years later, follow-up clinical evaluations were conducted in 94% of the original cohort. Clinical course during the interval period was assessed without knowledge of subjects' initial diagnostic and psychobiological status. Re-analysis of the original sleep data were performed with the added information of longitudinal clinical course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Depressed subjects who had a unipolar course showed reduced REM latency, higher REM density, and more REM sleep (specifically in the early part of the night) compared with depressed adolescents who converted to bipolar disorder and controls who remained free from psychopathology at follow-up. In contrast to the unipolar group, depressed subjects who would later switch to bipolar disorder had demonstrated more stage 1 sleep and diminished stage 4 sleep.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These preliminary results indicate that some of the observed variability in EEG sleep measures in adolescent depression appear to be confounded by latent bipolar illness. The findings also suggest that sleep regulatory changes associated with unipolar versus bipolar mood disorders may be different.</AbstractText><CopyrightInformation>Copright 2002 Elsevier Science BV.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Uma</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90024-1759, USA. urao@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Ronald E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Neal D</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Douglas E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH030915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH062464</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01419</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA014037</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH41712</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AA08746</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="Y">Adolescent Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>11</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12128239</ArticleId><ArticleId IdType="pii">S0165032701003962</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(01)00396-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16469389</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>92</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment in bipolar disorder in old age: literature review and findings in manic patients.</ArticleTitle><Pagination><MedlinePgn>125-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Descriptions of aged patients with bipolar (BP) disorder have commented on cognitive impairments. However, the literature regarding cognitive test performance in this population has apparently been scant.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">1. We reviewed studies reporting cognitive performance in aged BP patients. 2. We compared the performance of elderly BP manic patients and aged community comparison subjects on the Mini-Mental State Examination (MMSE) and the Mattis Dementia Rating Scale (DRS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1. Seven published studies of cognitive measures in aged BP patients were identified. They utilized different assessment methods and addressed different illness states, but they indicate impairments in these patients. 2. In our sample, the manic patients (n=70) had lower MMSE scores and DRS scores than did the comparison subjects (n=37). In these patients, cognitive scores were not significantly associated with Mania Rating Scale scores.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The patients in our study were assessed cross-sectionally, and they were treated naturalistically.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Manic or depressed BP elders have impaired cognitive function; in some patients these impairments may persist. Research characterizing these impairments and their clinical implications is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Institute of Geriatric Psychiatry, Weill Medical College of Cornell University, and Payne Whitney Westchester, USA. ryoung@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>C F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schulberg</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 MH067028</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-MH068638</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH32956</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>48</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16469389</ArticleId><ArticleId IdType="pii">S0165-0327(05)00412-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.12.042</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27989245</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>The clinical features of mania and their representation in modern diagnostic criteria.</ArticleTitle><Pagination><MedlinePgn>1013-1029</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291716003238</ELocationID><Abstract><AbstractText>This review seeks to determine the degree to which modern operationalized diagnostic criteria for mania reflect the clinical features of mania described historically by expert textbook authors. Clinical descriptions of mania appearing in 18 textbooks published between 1899 and 1956 were reviewed and compared to the criteria for mania from six modern operationalized diagnostic systems. Twenty-two prominent symptoms and signs were reported by five or more authors. Two symptoms (elevated mood and grandiosity) and four signs (hyperactivity, pressured speech, irritability, and new activities with painful consequences) were reported by every author. A strong relationship was seen between the frequency with which the clinical features were reported and the likelihood of their inclusion in modern diagnostic systems. However, many symptoms and signs including impulsivity, hypersexuality, mood lability, altered moral standards, increased humor, hypergraphia, and a vigorous physical appearance were not included in any modern criteria. Indeed, DSM-5 contains only eight of the historically noted clinical features. We conclude that modern operationalized criteria for mania well reflect symptoms and signs frequently reported by historical experts. This suggests that the clinical construct of mania has been relatively stable in western Psychiatry since the turn of the 20th century. However, many useful clinical features of mania described in these textbooks are missing from these criteria thereby illustrating the limitations of clinical evaluations restricted to the assessment of only current diagnostic criteria. The disorders we study and treat are considerably richer clinically than is reflected in the DSM criteria which we use to diagnose them.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kendler</LastName><ForeName>K S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Virginia Institute for Psychiatric and Behavioral Genetics,Virginia Commonwealth University,Richmond,VA,USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DSM</Keyword><Keyword MajorTopicYN="N">Kraepelin</Keyword><Keyword MajorTopicYN="N">history</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">psychiatric nosology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27989245</ArticleId><ArticleId IdType="pii">S0033291716003238</ArticleId><ArticleId IdType="doi">10.1017/S0033291716003238</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3913975</PMID><DateCompleted><Year>1986</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5</Issue><PubDate><MedlineDate>1985 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Psychopathological and neurophysiological indicators in endogenous depression and the therapeutic effect of thymoleptics. I. Analysis of the clinical effect of antidepressive drugs with various pharmacological profiles].</ArticleTitle><Pagination><MedlinePgn>357-62</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Twarowska-Hauser</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Strzyzewksi</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chłopocka-Woźniak</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Markowski</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nowakowska</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rajewski</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rozek</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sydor</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zelechowska-Ruda</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Wykładniki psychopatologiczne i neurofizjologiczne endogennych depresji a efekt terapeutyczny tymoleptyków. I. Analiza klinicznego efektu działania leków przeciwdepresyjnych o zróznicowanym profilu farmakologicznym.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3913975</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">441684</PMID><DateCompleted><Year>1979</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>1979</Year></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Assessing vulnerability to schizophrenia or manic-depression in borderline states.</ArticleTitle><Pagination><MedlinePgn>105-10</MedlinePgn></Pagination><Abstract><AbstractText>In a discussion of the article on genetic determinants of borderline conditions by Siever and Gunderson, a phenotypic continuum between pure schizotypal and pure affective conditions is postulated. Many "borderline" cases are seen as attenuated forms of schizophrenia, schizoaffective psychosis, or manic-depression. A Venn diagram illustrates differences among syndromes described by Gunderson, Kernberg, Spitzer, and Klein ("hysteroid dysphoria"). Evidence is presented suggesting that Gunderson's borderline syndrome contains more schizotypal individuals than Kernberg's, whereas hysteroid dysphoria is nearer the affective pole of the continuum. A second diagram illustrates how the strength and nature of the genetic factors vary according to the syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">441684</ArticleId><ArticleId IdType="doi">10.1093/schbul/5.1.105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6803599</PMID><DateCompleted><Year>1982</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>139</Volume><Issue>5</Issue><PubDate><Year>1982</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Measurement of lithium concentrations in human tears.</ArticleTitle><Pagination><MedlinePgn>678-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>T B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Yablonski</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lesser</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Siris</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Rifkin</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013666" MajorTopicYN="N">Tears</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6803599</ArticleId><ArticleId IdType="doi">10.1176/ajp.139.5.678</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26142689</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><PubDate><Year>2015</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients.</ArticleTitle><Pagination><MedlinePgn>12-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.05.065</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00371-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The molecular understanding of bipolar disorder (BD) aetiology has advanced over the last years through the identification of peripheral disease biomarkers. Here, we have attempted to identify plasma biomarkers associated with distinct BD mood states.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma from BD patients with either a current manic (n=29) or mixed (n=17) mood state and healthy controls (n=53) were analysed using a multiplex immunoassay platform. A total of 145 hormones, growth factors, transport proteins and inflammatory factors were measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma levels of the hormones C-peptide, progesterone and insulin, and the inflammatory protein cancer antigen 125 were altered in both mood states. The hormone peptide YY and the growth factor trafficking protein sortilin were changed only in mania patients. Finally, the inflammatory factors haptoglobin, chemokine CC4 and matrix metalloproteinase 7 were altered specifically in mixed mood patients.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was limited by a small sample size, potential confounding effects of multiple drug treatments in the patient groups, and lack of dietary restrictions at sampling.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Plasma from mania and mixed mood BD patients revealed similar changes in proteins related to insulin signalling, suggesting that these could be trait biomarkers. However, mania patients showed specific changes in hormonal and growth factor functions and mixed mood patients had a higher number of changes in inflammation-related molecules. Further studies of these and other biomarker candidates will increase our understanding of the systemic biological pathways affected in different BD mood states. This could lead to the identification of differential surrogate readouts and potential new drug targets for improved treatment outcomes.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haenisch</LastName><ForeName>Frieder</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsaif</LastName><ForeName>Murtada</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guest</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmoune</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yolken</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Faith</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sheppard Pratt Health System, Baltimore, USA. Electronic address: faithbdickerson@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahn</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom. Electronic address: sb209@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006728">Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006728" MajorTopicYN="N">Hormones</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Inflammatory factors</Keyword><Keyword MajorTopicYN="N">Insulin</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Mixed mood states</Keyword><Keyword MajorTopicYN="N">Multiplex Immunoassay</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26142689</ArticleId><ArticleId IdType="pii">S0165-0327(15)00371-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.05.065</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21894105</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2011</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>23 Suppl 1</Volume><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Review: bipolar disorder and poetic genius.</ArticleTitle><Pagination><MedlinePgn>S62-8</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">"We of the craft (poets) are all crazy," remarked the 18th century British romanticist Lord Byron (George Gordon) about himself and his fellow poets. Implied in this statement is the notion that there exists a special kind of relationship between poets and being "crazy". A relationship between psychopathology and the artistic temperament is one of the oldest and most persistent of cultural notions; it is also one of the most contentious and controversial. The purpose of this exposition is to investigate if a correlation between bipolar disorder and poetic genius really does exist.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was conducted along with a review of Professor Jamison's treatise Touched with Fire: Manic Depressive Illness and the Artistic Temperament. A detailed case study of Lord Byron was also performed in order to gain a qualitative insight into the psyche of a notorious poet who was alleged to suffer from bipolar disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recent research employing systematic and biographical methodology has given strong support to a much higher rate of mood disorders in artistic populations than could be expected from chance alone. A British study spearheaded by Professor Jamison on living writers and artists revealed many overlapping mood, cognitive, and behavioral changes between hypomania and intense creative states. In the case of Lord Byron, the clinical hallmark of manic-depressive illness is its recurrent, episodic nature, which Byron had in an almost textbook manner. Byron also had a family history remarkable for its suicide in itself more likely to be associated with bipolar disorder than with any other condition.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Not all writers and artists suffer from major mood disorders. Likewise, most people who have a major mood disorder are not writers or artists. It seems counterintuitive that melancholy could be associated with artistic inspiration and productivity; the milder manic states would seem, at first thought, to be more obviously linked. In the case of Lord Byron, his temperament made him exquisitely responsive to virtually everything in his physical and psychological world; it gave him much of his great capacity for passion and understanding, as well as for suffering thus giving credence to the notion that there exists a correlation between bipolar disorder and poetic genius.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hankir</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Royal Oldham Hospital, Acute Pennine NHS Trust, UK. ahmedzakaria@doctors.org.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001154" MajorTopicYN="Y">Art</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="Y">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011037" MajorTopicYN="Y">Poetry as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21894105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27005426</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Why the hype about subtype? Bipolar I, bipolar II--it's simply bipolar, through and through!</ArticleTitle><Pagination><MedlinePgn>303-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867416641541</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Discipline of Psychiatry, Kolling Institute of Medical Research, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia Gin.malhi@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrow</LastName><ForeName>Yulisha</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Discipline of Psychiatry, Sydney Medical School and Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Darryl</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Fremantle, The University of Notre Dame Australia, Fremantle, WA, Australia School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Crawley, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Monash Alfred Psychiatry Research Centre, Central Clinical School, The Alfred and Monash University, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopwood</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyndon</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sydney Medical School, The University of Sydney, Sydney, NSW, Australia Mood Disorders Unit, Northside Clinic, Greenwich, NSW, Australia Director, ECT Services Northside Group Hospitals, Greenwich, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulder</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychological Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ajeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Psychology, University of New South Wales, Sydney, NSW, Australia Emergency Services in Australia, Australian Red Cross, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27005426</ArticleId><ArticleId IdType="pii">50/4/303</ArticleId><ArticleId IdType="doi">10.1177/0004867416641541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10221559</PMID><DateCompleted><Year>1999</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>187</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Personality disorders in bipolar II patients.</ArticleTitle><Pagination><MedlinePgn>245-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hospital Clinic, University of Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gastó</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10221559</ArticleId><ArticleId IdType="doi">10.1097/00005053-199904000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8639147</PMID><DateCompleted><Year>1996</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-8244</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>1996</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Behavior genetics</Title><ISOAbbreviation>Behav Genet</ISOAbbreviation></Journal><ArticleTitle>Assessing the statistical power to detect linkage in a sample of 51 bipolar affective disorder pedigrees.</ArticleTitle><Pagination><MedlinePgn>113-22</MedlinePgn></Pagination><Abstract><AbstractText>We used computer simulation method to address the question of power in an initial collaborative sample of 51 bipolar affective disorder pedigrees. Simulations were performed for all possible combinations using (1) two levels of diagnostic stringency, (2) three transmission models, (3) locus heterogeneity, and (4) different assumed phenocopy rates. Some of the factors affect the power to detect linkage are (1) the specification of the correct genetic model, (2) the degree of locus heterogeneity, and (3) the frequency of phenocopies. The first two assertions were supported by our simulation results, but varying the rates of phenocopy did not substantially alter the power of the sample until a critical point. However, it is important to point out that these results are dependent on the genetic models under study and on the use of the "correct" model (i.e., the one used to simulate the data). If we assume a dominant mode of inheritance and locus homogeneity, the power to detect linkage is 97.5% at a theta of .01. However, the power declines dramatically, to 60.5% and 14.7%, if only 75 and 50% of the families are linked, respectively. Locus heterogeneity has a similar effect on the power of the sample to exclude linkage. The relative lack of power in our data, in the presence of significant locus heterogeneity, and for an intermediate mode of inheritance, underscores the need for multicenter collaboration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>L C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Genetics Section, Institute of Psychiatry, De Crespigny Park, London SE5, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nöthen</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Körner</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fimmer</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Propping</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>McGuffin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Behav Genet</MedlineTA><NlmUniqueID>0251711</NlmUniqueID><ISSNLinking>0001-8244</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8639147</ArticleId><ArticleId IdType="doi">10.1007/BF02359889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 1993 Sep;5(1):40-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8220421</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1986 May;38(5):599-616</Citation><ArticleIdList><ArticleId IdType="pubmed">3459352</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Mar;50(3):205-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8439241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1987;21(4):551-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3326941</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1974 Sep;26(5):588-97</Citation><ArticleIdList><ArticleId IdType="pubmed">4422075</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1989 Apr;44(4):552-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2929598</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1989 Apr;44(4):543-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2929597</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Oct;83(19):7353-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2876423</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 1992;9(2):123-39</Citation><ArticleIdList><ArticleId IdType="pubmed">1639244</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1990 Feb;46(2):229-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2301393</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1955 Sep;7(3):277-318</Citation><ArticleIdList><ArticleId IdType="pubmed">13258560</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Nov;35(11):1304-11</Citation><ArticleIdList><ArticleId IdType="pubmed">708194</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1987;21(4):541-50</Citation><ArticleIdList><ArticleId IdType="pubmed">3326940</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1993 Aug;4(4):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8401581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Aug;48(8):764-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1986 Oct;39(4):513-27</Citation><ArticleIdList><ArticleId IdType="pubmed">3464203</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Neurol Neurochir. 1973 Nov-Dec;76(6):489-500</Citation><ArticleIdList><ArticleId IdType="pubmed">4781526</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1977 Nov;56(5):382-98</Citation><ArticleIdList><ArticleId IdType="pubmed">596231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1992 Dec;2(4):330-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1303289</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1986 Jul;39(1):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3019130</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1991 Sep 15;40(4):449-53</Citation><ArticleIdList><ArticleId IdType="pubmed">1684090</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 1987;4(4):255-66</Citation><ArticleIdList><ArticleId IdType="pubmed">3666434</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1986 Jun;42(2):393-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3741977</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 Oct;41(10):949-58</Citation><ArticleIdList><ArticleId IdType="pubmed">6332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 1988;5(1):35-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3282981</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1990 Aug;20(3):573-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2236365</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1993 Jul 15;48(2):94-102</Citation><ArticleIdList><ArticleId IdType="pubmed">8362931</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1961;37(162):28-32</Citation><ArticleIdList><ArticleId IdType="pubmed">13890818</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 1985;2(1):85-97</Citation><ArticleIdList><ArticleId IdType="pubmed">3863778</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1990 Feb;46(2):254-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2301395</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1992 Oct 23;258(5082):668-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1411576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10721685</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1180-4882</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatry &amp; neuroscience : JPN</Title><ISOAbbreviation>J Psychiatry Neurosci</ISOAbbreviation></Journal><ArticleTitle>Early- versus late-onset bipolar II disorder.</ArticleTitle><Pagination><MedlinePgn>53-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the clinical features and the outcome between patients with early- and late-onset bipolar II disorder.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Case series.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Outpatient private practice.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">One hundred and seventy-nine consecutive outpatients with bipolar II disorder presenting for treatment of a major depressive episode.</AbstractText><AbstractText Label="OUTCOME MEASURES" NlmCategory="METHODS">Duration of illness, severity of depression, recurrences, psychosis, chronicity, atypical features and comorbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with early-onset (before 20, 25 or 30 years of age) bipolar II disorder had a significantly longer duration of illness and more recurrences compared with patients with late-onset (after 20, 25 or 30 years of age) bipolar II disorder. All other variables were not significantly different between the 2 groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Indicators of worse outcome (severity of depression, psychosis, chronicity, comorbidity) were not significantly different between patients with early- and late-onset bipolar II disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Morgagni Public Hospital, Forlì, Italy. f.benazzi@fo.nettuno.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Psychiatry Neurosci</MedlineTA><NlmUniqueID>9107859</NlmUniqueID><ISSNLinking>1180-4882</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10721685</ArticleId><ArticleId IdType="pmc">PMC1407699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Nerv Ment Dis. 1980 Oct;168(10):611-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7420069</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Oct;39(10):1157-67</Citation><ArticleIdList><ArticleId IdType="pubmed">7125846</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 May;44(5):441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3579495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1987 Mar;26(2):176-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3584013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1988 Nov-Dec;15(3):255-68</Citation><ArticleIdList><ArticleId IdType="pubmed">2975298</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1989 Nov;46(11):971-82; discussion 983</Citation><ArticleIdList><ArticleId IdType="pubmed">2684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Jul;149(7):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">1609864</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Aug;149(8):999-1010</Citation><ArticleIdList><ArticleId IdType="pubmed">1353322</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Sep;49(9):703-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1514875</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Jun;50(6):457-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8498880</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Jul;28(3):155-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8408978</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Feb;151(2):210-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8296891</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1993 Sep-Oct;34(5):303-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7864264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):4S-14S</Citation><ArticleIdList><ArticleId IdType="pubmed">8707999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996 Nov;57(11):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8968311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Apr;43(2):163-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9165385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Oct;46(1):73-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9387089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1998 Feb;18(1):1</Citation><ArticleIdList><ArticleId IdType="pubmed">9472835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1998 Jan;23(1):51-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9505060</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1998 Mar-Apr;39(2):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9515190</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 1998;7(2):76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9614596</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1998 Spring;11(1):29-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9686750</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Oct;155(10):1398-406</Citation><ArticleIdList><ArticleId IdType="pubmed">9766772</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1999 Jan-Feb;40(1):80-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9924882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1999 May;24(3):244-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10354659</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jun 30;86(3):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10482345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Sep;55(1):63-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10512608</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Aug;134(8):919-22</Citation><ArticleIdList><ArticleId IdType="pubmed">879359</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Jan;38(1):58-61</Citation><ArticleIdList><ArticleId IdType="pubmed">7458569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31076186</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>06</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Functional remediation improves bipolar disorder functioning with no effects on brain-derived neurotrophic factor levels.</ArticleTitle><Pagination><MedlinePgn>701-710</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(19)30233-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2019.04.002</ELocationID><Abstract><AbstractText>The main aim of this study is to evaluate the impact of functional remediation (FR) in serum brain derived neurotrophic factor (BDNF) levels in euthymic adult patients with Bipolar Disorder (BD). A total of 128 participants were recruited at the Hospital Clinic of Barcelona. They were assessed at baseline and at the end of follow-up by the means of Hamilton Depression Scale (HAM-D), Young Mania Rating Scale (YMRS) and Functioning Assessment Short Test (FAST), as well as a clinical structured interview to collect clinical and demographic variables of interest. Blood samples were also collected to assess BDNF levels. After baseline assessment, patients received FR, Psychoeducation or treatment as usual (TAU). One hundred and two out of 126 participants finished the study distributed as follows: FR group (n = 39); Psychoeducation group (n = 47) and TAU group (n = 16). Longitudinal repeated-measures analyses addressing the treatment effect on BDNF levels showed non-significant differences between the three groups (Pillai's trace = 0.06; F<sub>(2,97)</sub>= 0.28; p = 0.75), suggesting no interaction between treatment allocation and time on BDNF levels. The results of this study suggest that FR has no effect on peripheral BDNF levels in euthymic patients with BD, despite the improvement in psychosocial functioning.</AbstractText><CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>Caterina Del Mar</ForeName><Initials>CDM</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valls</LastName><ForeName>Elia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Adriane R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Universidade Federal do Rio Grande do Sul (UFRGS), Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solé</LastName><ForeName>Brisa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montejo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meseguer</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, University of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mental Health Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)-Hospital del Mar, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Aran</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain. Electronic address: amartiar@clinic.ub.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomioka</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar and Depressive Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Hospital Clinic of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>7171WSG8A2</RegistryNumber><NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">BDNF</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Functional remediation</Keyword><Keyword MajorTopicYN="Y">Functioning</Keyword><Keyword MajorTopicYN="Y">Psychoeducation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31076186</ArticleId><ArticleId IdType="pii">S0924-977X(19)30233-0</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2019.04.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2561683</PMID><DateCompleted><Year>1990</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Platelet [3H]-imipramine binding according to DSM-III subtypes of depression.</ArticleTitle><Pagination><MedlinePgn>33-40</MedlinePgn></Pagination><Abstract><AbstractText>The question of the previously reported changes in the density of high-affinity binding sites for [3H]-imipramine (IMI) in platelets from depressed patients was reexamined among the different diagnostic subtypes of depression according to the DSM-III classification and taking into account the possible influence of the low-affinity binding site. Using a least-square computer-assisted analysis, a precise determination of the [3H]-IMI binding parameters exclusively in relationship to the high-affinity site was performed in 46 untreated depressed patients and compared to 35 healthy controls. The results revealed a clear and highly significant 22% decrease in the maximal density (Bmax) of [3H]-IMI binding in all of the depressed patients compared to controls with no change in affinity values. Considering the diagnostic subgroups, we found that all the bipolar patients, the depressed as well as the euthymic or manic ones, had very low Bmax values and that some of them also exhibited an unusual low-affinity binding. Mean Bmax of the unipolar and dysthymic patients significantly decreased when compared to controls, although the Bmax values showed a large variability. Only dysthymic patients presented Bmax values which were significantly associated to symptom severity as assessed by the Hamilton Depression Rating Scale scores. Our results confirm the lower density of platelet [3H]-IMI binding in affective disorders, particularly in bipolar patients, and also suggest that this biological parameter is a trait marker in bipolar depression and a state marker in dysthmic disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeanningros</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unité de Psychiatrie Biologique, CNRS, Faculté de Médecine, CHU Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gronier</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C027775">imipramine receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="Y">Carrier Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011955" MajorTopicYN="Y">Receptors, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2561683</ArticleId><ArticleId IdType="pii">118589</ArticleId><ArticleId IdType="doi">10.1159/000118589</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16390907</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>163</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Adjunctive lamotrigine as a possible mania inducer in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>159-60</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raskin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Teitelbaum</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zislin</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Durst</LastName><ForeName>Rimona</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16390907</ArticleId><ArticleId IdType="pii">163/1/159-a</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.163.1.159-a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17825922</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>107</Volume><Issue>1-3</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Is donepezil useful for improving cognitive dysfunction in bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>237-40</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive dysfunctions are being recognized as a major roadblock to functional recovery in patients with bipolar disorders. Little is known about the treatment of these cognitive dysfunctions. Donepezil, approved to treat memory dysfunction in Alzheimer's disease, is evaluated for cognitive dysfunctions common in bipolar disorder. Of concern is some evidence that donepezil may trigger affective instability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All bipolar disordered patients in a private practice setting treated with donepezil for memory problems were analyzed. Patients were assessed for memory improvement and change in psychiatric status with the Clinical Global Impression of Improvement Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine of 58 patients (67%) reported improvement with a mean score of 1.82 (standard deviation+/-0.82). Nine treatments were stopped because of side effects and 4 showed no response. No bipolar I patient received benefits. Thirty-six of 43 (84%) of bipolar II patients showed improvement. Fifty percent of bipolar NOS showed improvement. Four bipolar I patients (57%), 1 bipolar II patient (2%) and 2 bipolar NOS patients (25%) stopped donepezil due to worsening affective symptoms.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This is a naturalistic case series with a single evaluator. Other medications used in treatment were changed as clinically indicated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case series suggests utility for donepezil in the treatment of cognitive problems associated with bipolar II disorder and bipolar disorder NOS. Bipolar I patients showed no improvement and a concerning trend to destabilize with donepezil treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Tammas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>503 Remington St., Fort Collins, Colorado 80524, United States. DepressionBipolarClinic@comcast.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011331" MajorTopicYN="N">Private Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17825922</ArticleId><ArticleId IdType="pii">S0165-0327(07)00280-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2007.07.027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12807371</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>108</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Rapid-cycling bipolar disorder: effects of long-term treatments.</ArticleTitle><Pagination><MedlinePgn>4-14</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare responses to long-term treatment of rapid-cycling (RC) vs. non-RC bipolar disorder patients and assess relative effectiveness of specific agents in RC patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Studies identified by literature searching were analyzed for effects of RC status and treatment-type on clinical outcome (recurrence or non-improvement per exposure-time), using random-effects methods to estimate pooled rates and their 95% CI for quantitative meta-analytic modeling.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data were obtained from 16 reports with 25 trial-arms involving 1856 (905 RC and 951 non-RC) patients treated with carbamazepine, lamotrigine, lithium, topiramate, or valproate, alone or with other agents over an average of 47.5 months (7347 total patient-years). Estimated RC prevalence was 15.4%. Crude rates (%/month) of recurrence (2.31/1.20) and clinical non-improvement (1.93/0.49) averaged 2.9-fold greater in RC vs. non-RC subjects. The pooled RC/non-RC risk ratio (RR) for inferior treatment-response (in 13 direct comparisons) was 1.40 (CI 1.26-1.56; P &lt; 0.0001). Pooled crude recurrence and non-improvement rates suggested no clear advantage for any treatment, nor superiority for anticonvulsants over lithium. However, only lithium vs. carbamazepine could be directly compared (in four treatment-arms) meta-analytically in RC patients (RR = 0.93, CI 0.74-1.18, indicating no difference in effectiveness).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As expected, RC was associated with lower effectiveness of all treatments evaluated. Direct comparisons of specific treatment alternatives for RC patients were rare, and provided no secure evidence of superiority of any treatment. Additional long-term studies comparing RC/non-RC patients randomized to specific treatments are required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience Program, Harvard Medical School, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-31142</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-47370</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Psychiatr Scand. 2003 Jul;108(1):1-3</RefSource><PMID Version="1">12807370</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12807371</ArticleId><ArticleId IdType="pii">126</ArticleId><ArticleId IdType="doi">10.1034/j.1600-0447.2003.00126.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18441528</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2008</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-033X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale.</ArticleTitle><Pagination><MedlinePgn>264-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000128325</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychosis is present in 50% or more of patients with bipolar mania and is commonly evaluated in clinical research by means of the Positive and Negative Syndrome Scale (PANSS). The aim of the present analysis was to investigate the psychotic dimensions of bipolar disorder and its contributing symptoms based on a factor analysis of baseline PANSS scores and to compare them with those identified in studies of patients with schizophrenia and bipolar disorder.</AbstractText><AbstractText Label="SAMPLING AND METHODS" NlmCategory="METHODS">Baseline data were analyzed from two 3-week, double-blind, placebo-controlled studies of risperidone monotherapy for acute mania associated with bipolar I disorder (n = 535). Inclusion criteria were a DSM-IV diagnosis of bipolar I disorder with manic features, with or without psychotic features, age &gt; or =18 years, and mean baseline Young Mania Rating Scale scores &gt; or =20. A principal component analysis of the 30 PANSS item scores of the 535 patients with a diagnosis of a manic episode at baseline was conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five factors were extracted by the analysis: anxiety (13.4% of the variance), negative symptoms (12.3%), depression (10.5%), excitement (10.3%), and positive symptoms (8.7%). Similar factors, in particular the negative, excitement, and positive factors, have been identified in patients with schizophrenia. There was an absence of a cognitive factor supporting the notion that bipolar patients may present fewer cognitive symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of the present analysis and those of other studies indicate similarities in psychotic symptom domains, as measured by the PANSS, in patients with bipolar mania and schizophrenia. Future analyses will address the effects of treatment on the identified factors.</AbstractText><CopyrightInformation>(c) 2008 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindenmayer</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA. Lindenmayer@NKI.rfmh.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossie</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Kujawa</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Young</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Canuso</LastName><ForeName>Carla M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18441528</ArticleId><ArticleId IdType="pii">000128325</ArticleId><ArticleId IdType="doi">10.1159/000128325</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23560889</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The immature dentate gyrus represents a shared phenotype of mouse models of epilepsy and psychiatric disease.</ArticleTitle><Pagination><MedlinePgn>405-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12064</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">There is accumulating evidence to suggest psychiatric disorders, such as bipolar disorder and schizophrenia, share common etiologies, pathophysiologies, genetics, and drug responses with many of the epilepsies. Here, we explored overlaps in cellular/molecular, electrophysiological, and behavioral phenotypes between putative mouse models of bipolar disorder/schizophrenia and epilepsy. We tested the hypothesis that an immature dentate gyrus (iDG), whose association with psychosis in patients has recently been reported, represents a common phenotype of both diseases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Behaviors of calcium/calmodulin-dependent protein kinase II alpha (α-CaMKII) heterozygous knock-out (KO) mice, which are a representative bipolar disorder/schizophrenia model displaying iDG, and pilocarpine-treated mice, which are a representative epilepsy model, were tested followed by quantitative polymerase chain reaction (qPCR)/immunohistochemistry for mRNA/protein expression associated with an iDG phenotype. In vitro electrophysiology of dentate gyrus granule cells (DG GCs) was examined in pilocarpine-treated epileptic mice.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The two disease models demonstrated similar behavioral deficits, such as hyperactivity, poor working memory performance, and social withdrawal. Significant reductions in mRNA expression and immunoreactivity of the mature neuronal marker calbindin and concomitant increases in mRNA expression and immunoreactivity of the immature neuronal marker calretinin represent iDG signatures that are present in both mice models. Electrophysiologically, we have confirmed that DG GCs from pilocarpine-treated mice represent an immature state. A significant decrease in hippocampal α-CaMKII protein levels was also found in both models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data have shown iDG signatures from mouse models of both bipolar disorder/schizophrenia and epilepsy. The evidence suggests that the iDG may, in part, be responsible for the abnormal behavioral phenotype, and that the underlying pathophysiologies in epilepsy and bipolar disorder/schizophrenia are strikingly similar.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CNS, Astellas Research Institute of America LLC, Skokie, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Katsunori</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hagihara</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kogan</LastName><ForeName>Jeffrey H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Miyake</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tajinda</LastName><ForeName>Katsunori</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Walton</LastName><ForeName>Noah M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Adam K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Heusner</LastName><ForeName>Carrie L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qian</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Miyakawa</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Mitsuyuki</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064032">Calbindin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>01MI4Q9DI3</RegistryNumber><NameOfSubstance UI="D010862">Pilocarpine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="Y">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064032" MajorTopicYN="N">Calbindin 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="Y">Dentate Gyrus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055724" MajorTopicYN="N">Electrophysiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010862" MajorTopicYN="N">Pilocarpine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">calbindin</Keyword><Keyword MajorTopicYN="N">calcium/calmodulin-dependent protein kinase II alpha</Keyword><Keyword MajorTopicYN="N">calretinin</Keyword><Keyword MajorTopicYN="N">dentate gyrus</Keyword><Keyword MajorTopicYN="N">doublecortin</Keyword><Keyword MajorTopicYN="N">neuronal immaturity</Keyword><Keyword MajorTopicYN="N">pilocarpine</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword><Keyword MajorTopicYN="N">seizures</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23560889</ArticleId><ArticleId IdType="doi">10.1111/bdi.12064</ArticleId><ArticleId IdType="pmc">PMC3752967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Mol Cell Biol. 2011 Oct;3(5):270-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21933804</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Dec 19;27(51):14012-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18094240</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2006 Dec;47(12):2104-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17201710</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Genet. 2011 Nov 25;12:154</Citation><ArticleIdList><ArticleId IdType="pubmed">22118685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1992 Sep 1;149(5):1657-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1387148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2008 Sep 10;1:6</Citation><ArticleIdList><ArticleId IdType="pubmed">18803808</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 9;97(10):5604-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10779547</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2012 Apr 21;230(1):182-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22348894</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8987-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12851457</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(4):e5320</Citation><ArticleIdList><ArticleId IdType="pubmed">19399173</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2011;750:61-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21618083</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Behav. 2009 Jan;14 Suppl 1:65-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18796338</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2010 Oct;32(8):1300-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20846322</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 1996 Mar;108(3):389-403</Citation><ArticleIdList><ArticleId IdType="pubmed">8801119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Apr 30;28(18):4836-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18448660</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Jul 15;58(2):85-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16038679</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol (Napoli). 1993 Feb;15(1):62-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8456597</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2008 Jul 30;172(2):143-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18550176</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2007 Oct;207(2):329-49</Citation><ArticleIdList><ArticleId IdType="pubmed">17714705</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2006 Jul 7;140(3):981-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16632208</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6852-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7624331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2002 Sep;82(5):1065-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12358754</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 May 1;71(9):836-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22365727</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1990 Oct 29;531(1-2):88-94</Citation><ArticleIdList><ArticleId IdType="pubmed">1963106</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2012 Dec;238(2):156-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22960187</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Behav. 2010 Oct;19(2):134-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20708439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2009 Apr;87(5):1135-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19025771</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 Jan;45(1):234-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21856425</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Res. 2008 May;79(2-3):213-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18394865</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2008 Jun;49 Suppl 5:26-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18522598</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Res. 2012 Jan;98(1):14-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21920703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2011;22(3):267-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21591906</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2007 Oct 26;149(2):465-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17904758</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 May 26;70(4):687-702</Citation><ArticleIdList><ArticleId IdType="pubmed">21609825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2005 Nov;6(11):863-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16261180</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2009 Sep;219(1):284-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19500573</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2012 May;37(6):1500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22278095</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2011 Dec;52(12):e194-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22050399</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Aug 23;65(4):535-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16116112</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2009 Jul;8(5):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19493016</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2012 Feb;53(2):e37-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22220741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1998 May 15;509 ( Pt 1):39-45</Citation><ArticleIdList><ArticleId IdType="pubmed">9547379</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Jul 10;2:e135</Citation><ArticleIdList><ArticleId IdType="pubmed">22781168</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Nov 14;278(1-2):322-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6357353</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 May 4;107(18):8434-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20404165</ArticleId></ArticleIdList></Reference><Reference><Citation>Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 2005 Apr 21;156(1):67-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15862629</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2005 Sep;46(9):1389-400</Citation><ArticleIdList><ArticleId IdType="pubmed">16146433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Mar 15;23(6):2440-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12657704</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Behav. 2011 Feb;20(2):257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">21237720</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Mar 25;13(4):501-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11930170</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2010 May 20;6(5):e1000962</Citation><ArticleIdList><ArticleId IdType="pubmed">20502679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2007;18(2):93-114</Citation><ArticleIdList><ArticleId IdType="pubmed">17593874</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1992 Mar;12(3):1101-14</Citation><ArticleIdList><ArticleId IdType="pubmed">1532025</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Mar 31;159(3):1003-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19356684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20449978</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2010</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><MedlineDate>2010 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Neuroimmunology of bipolar affective disorder].</ArticleTitle><Pagination><MedlinePgn>27-38</MedlinePgn></Pagination><Abstract><AbstractText>Previous neuroimmunological studies focused mostly on depression, regardless of its diagnostic category. In this paper, the studies on the immunological system in patients with bipolar affective illness, including manic episode, have been presented. Research possibilities of neuroimmunology of affective disorders using molecular-genetic methods have also been shown. The studies on the neuroimmunology of depression have always been connected with studies on changes in the immunological system related to stress situations. Disturbances of the immunological system regulation have features of either decrease or pathological increase of the immunological system, with increased activity of pro-inflammatory cytokines (interleukin 1 and 6, interferon). Some pathogenic role for the disturbances of immunological system in depression is also played by viral infections (herpes, Borna viruses). The changes of the immunological system in mania are mostly similar to those observed during depression. An increase of activity of pro-inflammatory cytokines, connected with the lymphocyte Th1 system is especially evident. Like in depression, the role of viral infections has been pointed out (herpes, Borna, parvovirus B19). The oldest mood-stabilizing drug, lithium, has been shown to have strong action against herpes viruses. Molecular-genetic studies point to an association of some genes of the immunological system with both bipolar disorder and schizophrenia. An association of some genes with a predisposition to depression and efficacy of antidepressant drugs has also been shown.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Remlinger-Molenda</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinika Psychiatrii Dorosłych UM w Poznaniu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz</ForeName><Initials>J</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Neuroimmunologia choroby afektywnej dwubiegunowej.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="N">Herpesviridae Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="Y">Neuroimmunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20449978</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32056918</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>266</Volume><PubDate><Year>2020</Year><Month>04</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Can olfactory dysfunction be a marker of trait or states of bipolar disorders? A comprehensive review.</ArticleTitle><Pagination><MedlinePgn>498-502</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(19)32073-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2020.01.081</ELocationID><Abstract><AbstractText Label="BACKGROUND">Olfactory deficits (OD) are reported as markers for a large spectrum of neuro-psychiatric disorders. Alterations can concern perception, identification, discrimination and assignment of odour's valence of olfaction process. We propose a comprehensive review to summarize which kind of OD were reported in bipolar disorders (BD) and in which phase of the disease, to know if they could be a marker of state or trait.</AbstractText><AbstractText Label="METHODS">A Systematic Literature Review was conducted using PRISMA guidelines to include all studies assessing olfaction with objective measures in BD.</AbstractText><AbstractText Label="RESULTS">9 studies were identified. All of them have assessed odour identification and 3 reported deficits mainly in patients with psychotic features or elements of illness severity in comparison to healthy subjects. There is no difference in threshold of perception between BD patients and controls and it is no possible to conclude for discrimination because only one study has assessed this dimension in comparison to control. We cannot conclude for hedonic value of odours regarding these studies.</AbstractText><AbstractText Label="LIMITATIONS">These studies are very incomplete because only one has evaluated all the processes involved in olfaction process.</AbstractText><AbstractText Label="CONCLUSIONS">In light of this review, evidence is still missing to unveil potential disturbances of olfactory process as a marker of BD. These new avenues of research could help to clarify the links between OD and BD and provide information on the pathophysiology of the disorder according to the impaired dimension.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unité Perception et Mémoire, Institut Pasteur, UMR3571, CNRS, Paris, France; Université de Paris, F-75006 Paris, France; Department of Psychiatry, Service Hospitalo-Universitaire, GHU Paris Psychiatrie &amp; Neurosciences, F-75014 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyrel</LastName><ForeName>Manon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris cedex 10, France. Electronic address: manon.meyrel@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigot</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unité Perception et Mémoire, Institut Pasteur, UMR3571, CNRS, Paris, France; Sorbonne université, Collège doctoral, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unité Perception et Mémoire, Institut Pasteur, UMR3571, CNRS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lledo</LastName><ForeName>Pierre-Marie</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Unité Perception et Mémoire, Institut Pasteur, UMR3571, CNRS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dargél</LastName><ForeName>Aroldo A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Unité Perception et Mémoire, Institut Pasteur, UMR3571, CNRS, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009812" MajorTopicYN="N">Odorants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Emotion</Keyword><Keyword MajorTopicYN="Y">Odour identification</Keyword><Keyword MajorTopicYN="Y">Olfaction</Keyword><Keyword MajorTopicYN="Y">Perceptive bias</Keyword><Keyword MajorTopicYN="Y">Valence</Keyword></KeywordList><CoiStatement>Declarations of Competing Interest None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32056918</ArticleId><ArticleId IdType="pii">S0165-0327(19)32073-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2020.01.081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30516584</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5873</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>04</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Missing a beat: assessment of circadian rhythm abnormalities in bipolar disorder in the genomic era.</ArticleTitle><Pagination><MedlinePgn>29-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YPG.0000000000000215</ELocationID><Abstract><AbstractText>Circadian rhythm abnormalities have been recognized as a central feature of bipolar disorder (BD) but a coherent biological explanation for them remains lacking. Using genetic mutation of 'clock genes', robust animal models of mania and depression have been developed that elucidate key aspects of circadian rhythms and the circadian clock-mood connection. However, translation of this knowledge into humans remains incomplete. In recent years, very large genome-wide association studies (GWAS) have been conducted and the genetic underpinnings of BD are beginning to emerge. However, these genetic studies in BD do not match well with the evidence from animal studies that implicate the circadian clock in mood regulation. Even larger GWAS have been conducted for circadian phenotypes including chronotype, rhythm amplitude, sleep duration, and insomnia. These studies have identified a diverse set of associated genes, including a minority with previously well-characterized functions in the circadian clock. Taken together, the data from recent GWAS of BD and circadian phenotypes indicate that the genetic organization of the circadian clock, both in health and in BD is complex. The findings from GWAS elucidate potentially novel circadian mechanism that may be partly distinct from those identified in animal models. Pleiotropy, epistasis and nongenetic factors may play important roles in regulating circadian rhythms, some of which may underlie circadian rhythm disturbances in BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Circadian Biology, VA San Diego Healthcare System, University of California San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX003431</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30516584</ArticleId><ArticleId IdType="doi">10.1097/YPG.0000000000000215</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29243543</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>06</Month></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A kainate receptor GluK4 deletion, protective against bipolar disorder, is associated with enhanced cognitive performance across diagnoses in the TwinsUK cohort.</ArticleTitle><Pagination><MedlinePgn>393-401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15622975.2017.1417637</ELocationID><Abstract><AbstractText><b>Objectives:</b> Cognitive deficits are a common feature of neuropsychiatric disorders. We investigated the relationship between cognitive performance and a deletion allele within GluK4 protective against risk for bipolar disorder, in 1,642 individuals from the TwinsUK study. <b>Methods:</b> Cognitive performance was assessed using the National Adult Reading Test, four CANTAB tests (Spatial Working Memory, Paired Associates Learning, Pattern Recognition Memory and Reaction Time), and two Principal-Component Analysis-derived factors. Performance in individuals homozygous for the insertion allele was compared to deletion carriers and analysis was adjusted for age of diagnosis, medication and clinical diagnosis. <b>Results:</b> Individuals with the GluK4 protective deletion allele performed significantly better in Spatial Working Memory compared to insertion homozygotes when adjusted for a clinical diagnosis. GluK4 deletion carriers who had a mental health problem (predominately depression) showed better performance in visuo-spatial ability and mental processing speed compared to individuals with mental health problems homozygous for the insertion. <b>Conclusions:</b> These findings of genotype-dependent cognitive enhancement across clinical groups support the potential clinical use of the GluK4 deletion allele in personalised medicine strategies and provide new insight into the relationship between genetic variation and mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koromina</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a School of Life Sciences, Medical School , University of Nottingham , Nottingham , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flitton</LastName><ForeName>Miles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a School of Life Sciences, Medical School , University of Nottingham , Nottingham , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellor</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>a School of Life Sciences, Medical School , University of Nottingham , Nottingham , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Helen Miranda</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>a School of Life Sciences, Medical School , University of Nottingham , Nottingham , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514872">GRIK4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018092">Receptors, Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018092" MajorTopicYN="N">Receptors, Kainic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">GluK4</Keyword><Keyword MajorTopicYN="Y">Kainate receptors</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">deletion allele</Keyword><Keyword MajorTopicYN="Y">mood disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29243543</ArticleId><ArticleId IdType="doi">10.1080/15622975.2017.1417637</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15225146</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Psychoeducation in bipolar patients with comorbid personality disorders.</ArticleTitle><Pagination><MedlinePgn>294-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The co-occurrence of personality and bipolar disorders is quite common. Bipolar patients with personality disorders have been described as having poorer outcome than 'pure' bipolar patients. However, from a combined-approach point of view, a little has been done to improve the course of these patients. Psychoeducation has shown its efficacy in the prevention of relapses in the bipolar population but, to date, no data is available on its efficacy in the management of bipolar patients with personality disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The present study shows a subanalysis from a single-blind randomized prospective clinical trial on the efficacy of group psychoeducation in bipolar I patients. Bipolar patients fulfilling DSM-IV criteria for any personality disorder were randomized to either psychoeducational treatment or a non-structured intervention. There were 22 patients in the control group and 15 in the psychoeducation group. All patients received naturalistic pharmacological treatment as well. The follow-up phase comprised 2 years where all patients continued receiving naturalistic treatment without psychological intervention and were assessed monthly for several outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the end of the follow-up phase (2 years), a 100% of control group patients fulfilled criteria for recurrence versus a 67% in the psychoeducation group (p &lt; 0.005). Patients included in the psychoeducation group had a higher time-to-relapse and a significantly lower mean number of total, manic and depressive relapses. No significant differences regarding the number of patients who required hospitalization were found but the mean duration of days spent in the hospitalization room was significantly higher for the patients included in the control group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Psychoeducation may be a useful intervention for bipolar patients with comorbid personality disorders. Further studies should address the efficacy of specifically tailored interventions for this common type of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Hospital Clinic University of Barcelona, IDIBAPS, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sánchez-Moreno</LastName><ForeName>José</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>Anabel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>María</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>José Manuel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Comes</LastName><ForeName>Mercè</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 2009 Aug;195(2):180; author reply 180-1</RefSource><PMID Version="1">19648558</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15225146</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00127.x</ArticleId><ArticleId IdType="pii">BDI127</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31748866</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Ambulatory monitoring and digital phenotyping in the diagnostics and treatment of bipolar disorders].</ArticleTitle><Pagination><MedlinePgn>1215-1220</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-019-00816-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Reliable and valid diagnostics and treatment of bipolar disorders and affective episodes are subject to extensive, especially methodological limitations in the clinical practice.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The use of smartphones and mobile sensor technology for improvement in diagnostics and treatment of bipolar disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Critical discussion of current research on the use of ambulatory monitoring and digital phenotyping with bipolar disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In many studies the observation periods were too short and the sensors applied were too inaccurate to enable reliable and valid detection of behavioral changes in the context of affective episodes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The clarification and operationalization of psychopathological constructs to allow for the measurement of objectively observable and ascertainable behavioral changes during depressive and (hypo)manic states are essential for the successful application of modern mobile technologies in the diagnostics and treatment of bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Severus</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland. Emanuel.Severus@uniklinikum-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebner-Priemer</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institut für Sportwissenschaft, Karlsruher Institut für Technologie, Karlsruhe, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mühlbauer</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritter</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institut für Sportwissenschaft, Karlsruher Institut für Technologie, Karlsruhe, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Ambulantes Monitoring und digitale Phänotypisierung in Diagnostik und Therapie bipolarer Erkrankungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018670" MajorTopicYN="Y">Monitoring, Ambulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068997" MajorTopicYN="N">Smartphone</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMDP system</Keyword><Keyword MajorTopicYN="N">Mobile sensors</Keyword><Keyword MajorTopicYN="N">Precision medicine</Keyword><Keyword MajorTopicYN="N">Psychopathology</Keyword><Keyword MajorTopicYN="N">Research domain criteria</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31748866</ArticleId><ArticleId IdType="doi">10.1007/s00115-019-00816-9</ArticleId><ArticleId IdType="pii">10.1007/s00115-019-00816-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Transl Psychiatry. 2017 Mar 7;7(3):e1053</Citation><ArticleIdList><ArticleId IdType="pubmed">28267146</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Mar;202(3):172-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23457180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Internet Res. 2018 Jul 20;20(7):e241</Citation><ArticleIdList><ArticleId IdType="pubmed">30030209</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2019 Feb;53(2):170-171</Citation><ArticleIdList><ArticleId IdType="pubmed">30545243</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2019 Feb;73(2):50-62</Citation><ArticleIdList><ArticleId IdType="pubmed">30565801</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2013 Aug 23;1:12</Citation><ArticleIdList><ArticleId IdType="pubmed">25505679</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2018 Oct 26;18(1):349</Citation><ArticleIdList><ArticleId IdType="pubmed">30367608</ArticleId></ArticleIdList></Reference><Reference><Citation>JMIR Ment Health. 2016 May 05;3(2):e16</Citation><ArticleIdList><ArticleId IdType="pubmed">27150677</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2019 Feb;53(2):119-128</Citation><ArticleIdList><ArticleId IdType="pubmed">30387368</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2008 Sep;23(6):430-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18515048</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2013 Aug 23;1:14</Citation><ArticleIdList><ArticleId IdType="pubmed">25505681</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2017 Feb 1;74(2):189-196</Citation><ArticleIdList><ArticleId IdType="pubmed">28002572</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2018 Dec 1;151:41-54</Citation><ArticleIdList><ArticleId IdType="pubmed">30099083</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Mar;109(3):222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14984395</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 May 14;11:126</Citation><ArticleIdList><ArticleId IdType="pubmed">23672542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervenarzt. 2017 May;88(5):538-548</Citation><ArticleIdList><ArticleId IdType="pubmed">28188401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 Feb;22(2):164-169</Citation><ArticleIdList><ArticleId IdType="pubmed">27922603</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2017 Oct 3;318(13):1215-1216</Citation><ArticleIdList><ArticleId IdType="pubmed">28973224</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2019 Feb 1;76(2):190-198</Citation><ArticleIdList><ArticleId IdType="pubmed">30540352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sensors (Basel). 2015 Nov 06;15(11):28070-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26561811</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2018 Jan 23;6(1):6</Citation><ArticleIdList><ArticleId IdType="pubmed">29359252</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2019 Apr 4;:1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">30944054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2015 Feb;30(2):228-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25555342</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2009 Dec;21(4):463-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19947781</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Oct;45(13):2691-704</Citation><ArticleIdList><ArticleId IdType="pubmed">26220802</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2019 Jun 7;9(1):162</Citation><ArticleIdList><ArticleId IdType="pubmed">31175283</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Jul 19;6:e856</Citation><ArticleIdList><ArticleId IdType="pubmed">27434490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27557395</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><PubDate><Year>2016</Year><Month>10</Month></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mixed-methods analysis of internalized stigma correlates in poorly adherent individuals with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>174-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2016.07.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-440X(16)30139-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Internalized stigma, which occurs when stigmatized individuals accept society's assessment and incorporate this assessment into their sense of self, is prevalent in individuals with bipolar disorder (BD). This study explored the correlates of internalized stigma in a research sample of patients with BD who were poorly adherent to their medications.</AbstractText><AbstractText Label="METHODS">Both quantitative and qualitative analyses were performed. Scores of 115 individuals with BD on the Internalized Stigma of Mental Illness (ISMI) scale were correlated with scores on the General Self-Efficacy (GSE) Scale, Brief Psychiatric Rating Scale (BPRS), Montgomery-Asberg Depression Rating Scale (MADRS), and Young Mania Rating Scale (YMRS). Regression was run for GSE (dependent variable) and ISMI (independent variable). In-depth qualitative interviews were conducted on a representative subsample (N=21).</AbstractText><AbstractText Label="RESULTS">Internalized stigma levels were moderately high. Internalized stigma and self-efficacy correlated, and internalized stigma related to self-efficacy after adjusting for demographic variables (age, gender, years of education), comorbidities, and symptom severity (BPRS and MADRS). Internalized stigma was also associated with the BD symptoms of depression, anxiety, guilt feelings, suspiciousness, and hallucinogenic behaviors. No association was found with mania.</AbstractText><AbstractText Label="CONCLUSIONS">Because internalized stigma has strong psychosocial and psychiatric symptom associations, it is recommended that clinicians address both societal stigma and internalized stigma. Strategies such as cognitive-behavioral therapy may help modify BD patients' internalized stigma.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howland</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Cleveland, OH, 44106. Electronic address: molly.howland@case.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Cleveland, OH, 44106; Neurological and Behavioral Outcomes Center, University Hospitals Case Medical Center, 10524 Euclid Avenue, Cleveland, OH, 44106. Electronic address: jennifer.levin@uhhospitals.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blixen</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Cleveland, OH, 44106. Electronic address: cxb28@case.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatsuoka</LastName><ForeName>Curtis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurological and Behavioral Outcomes Center, University Hospitals Case Medical Center, 10524 Euclid Avenue, Cleveland, OH, 44106; Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, 10900 Euclid Ave, Cleveland, OH, 44106; Department of Neurology, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH, 44106. Electronic address: cmt66@case.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Cleveland, OH, 44106; Neurological and Behavioral Outcomes Center, University Hospitals Case Medical Center, 10524 Euclid Avenue, Cleveland, OH, 44106; Department of Neurology, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH, 44106; Department of Psychiatry, Case Western Reserve University School of Medicine, 10524 Euclid Ave, Cleveland, OH, 44106. Electronic address: martha.sajatovic@uhhospitals.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH093321</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003674" MajorTopicYN="N">Defense Mechanisms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020377" MajorTopicYN="N">Self Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="Y">Social Stigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013240" MajorTopicYN="Y">Stereotyping</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27557395</ArticleId><ArticleId IdType="pii">S0010-440X(16)30139-0</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2016.07.012</ArticleId><ArticleId IdType="pmc">PMC5317182</ArticleId><ArticleId IdType="mid">NIHMS812091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Depress Anxiety. 2005;21(2):95-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15884092</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2012 Dec 29;12:239</Citation><ArticleIdList><ArticleId IdType="pubmed">23272796</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Soc Psychiatry. 2015 Feb;61(1):58-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24869852</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2012 Jul;53(5):484-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22036011</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2013 Mar 1;64(3):264-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23573532</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2013 Aug;54(6):665-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23601987</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2014 May 29;14:157</Citation><ArticleIdList><ArticleId IdType="pubmed">24885144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Sep 15;184:209-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26112330</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Dec;151(3):805-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24135506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Apr;130(1-2):323-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21055821</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Dec 15;230(2):436-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26421901</ArticleId></ArticleIdList></Reference><Reference><Citation>Community Ment Health J. 2015 Jul;51(5):606-12</Citation><ArticleIdList><ArticleId IdType="pubmed">25612794</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Sep;122(1-3):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20347271</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Feb 28;225(3):433-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25554354</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Nov 1;121(1):31-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14572622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2007 Jan;33(1):192-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16894025</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk Psikiyatri Derg. 2013 Winter;24(4):231-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24310089</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2005 Sep;17(3):324-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16262458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2014 Aug;202(8):583-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25010107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 May;69(1-3):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12103453</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2001 Dec;52(12):1627-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11726754</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Addict J. 2011 Nov 11;4:58-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23264842</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Nov;118(1-3):180-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19285349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychol. 2005 Sep;139(5):439-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16285214</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2011 Oct;23(5):224-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25379893</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jun 02;9(6):e98767</Citation><ArticleIdList><ArticleId IdType="pubmed">24887440</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1927-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12411230</ArticleId></ArticleIdList></Reference><Reference><Citation>West J Nurs Res. 2005 Mar;27(2):188-99; discussion 200-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15695576</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Public Health. 2014 Oct 27;72(1):37</Citation><ArticleIdList><ArticleId IdType="pubmed">25671110</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Dec 30;129(3):257-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15661319</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Endocrinol Lett. 2013;34(4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23803872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Res Med Sci. 2014 Feb;19(2):90-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24778660</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Res Treat. 2012;2012:724848</Citation><ArticleIdList><ArticleId IdType="pubmed">22550571</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Oct 30;189(3):339-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21715017</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2010 Dec;71(12):2150-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21051128</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2016 Jan;51(1):81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26433379</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2013 Nov 25;11:202</Citation><ArticleIdList><ArticleId IdType="pubmed">24268204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15992398</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2005</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>112</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>A case of hydrocephalus occlusus presenting as bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>159-62; discussion 162-3</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This case highlights the fact that manic and depressive symptoms can be related to hydrocephalus occlusus even in the absence of neurological symptoms.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Single case report.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A 22-year-old male patient presented with a 2-year history of manic and depressive symptoms. He was admitted to psychiatric in-patient care fulfilling sufficient criteria of bipolar disorder presenting with a hypomanic state. No neurological symptoms could be detected. Three months later, a MRI of the brain showed a hydrocephalus occlusus because of a space-occupying lesion of 5 mm in the lamina tecti obstructing the aqueduct of Silvius. The MRI also showed parahippocampal changes, which were probably related to the hydrocephalus. After the implantation of a ventriculo-peritoneal shunt, manic symptoms resolved, but the patient continued to suffer from adynamic symptoms. Follow-up MRIs over 3 years showed no progression of the lesion of unknown etiology.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this case, early routine neuroimaging might have reduced long-term brain damage. The case underlines that even in the absence of neurological symptoms, brain imaging in bipolar disorder might be crucial. The feasibility of routine brain imaging in bipolar patients is discussed.</AbstractText><CopyrightInformation>Copyright Blackwell Munksgaard 2005.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reisch</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospital of Social and Community Psychiatry, Bern, Switzerland. reisch@spk.unibe.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brekenfeld</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Barth</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006849" MajorTopicYN="N">Hydrocephalus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017287" MajorTopicYN="N">Ventriculoperitoneal Shunt</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15992398</ArticleId><ArticleId IdType="pii">ACP480</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2004.00480.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21281661</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5177</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pharmacology, biochemistry, and behavior</Title><ISOAbbreviation>Pharmacol Biochem Behav</ISOAbbreviation></Journal><ArticleTitle>Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania.</ArticleTitle><Pagination><MedlinePgn>304-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pbb.2011.01.017</ELocationID><Abstract><AbstractText>The present study aimed to investigate the effects of tamoxifen (TMX) on locomotor behavior and on the activities of mitochondrial respiratory chain complexes and creatine kinase (CK) in the brain of rats subjected to an animal model of mania induced by d-amphetamine (D-AMPH)-reversion and prevention protocols. The D-AMPH administration increased locomotor activity in saline-treated rats under prevention and reversion treatment; furthermore, there was evident reduction in the locomotion in the D-amphetamine group treated with TMX. D-AMPH significantly decreased the activity of mitochondrial respiratory chain complexes in saline-treated rats in prefrontal cortex, hippocampus, striatum and amygdala in both prevention and reversion treatment. Depending on the cerebral area and evaluated complex, TMX was able to prevent and reverse this impairment. A decrease in CK activity was also verified in the brain of rats when D-AMPH was administrated in both experiments; the administration of TMX reversed but not prevented the decrease in CK activity induced by D-AMPH. The present study demonstrated that TMX reversed and prevented the alterations in behavioral and energy metabolism induced by D-AMPH (alterations were also observed in bipolar disorder), reinforcing the need for more studies about inhibitors of PKC as possible targets for new medications in the treatment of bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Morgana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences and National Institute for Translational Medicine (INCT-TM), Postgraduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, 88806-000 Criciúma, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valvassori</LastName><ForeName>Samira S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Steckert</LastName><ForeName>Amanda V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Rochi</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Joana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Scaini</LastName><ForeName>Giselli</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flávio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Streck</LastName><ForeName>Emilio L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Zugno</LastName><ForeName>Alexandra I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Quevedo</LastName><ForeName>João</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Biochem Behav</MedlineTA><NlmUniqueID>0367050</NlmUniqueID><ISSNLinking>0091-3057</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>094ZI81Y45</RegistryNumber><NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>TZ47U051FI</RegistryNumber><NameOfSubstance UI="D003913">Dextroamphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Pharmacol Biochem Behav. 2011 Jul;99(1):112</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003913" MajorTopicYN="N">Dextroamphetamine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004579" MajorTopicYN="N">Electron Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>01</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21281661</ArticleId><ArticleId IdType="pii">S0091-3057(11)00032-3</ArticleId><ArticleId IdType="doi">10.1016/j.pbb.2011.01.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20433320</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2010</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1360-0567</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of mental health (Abingdon, England)</Title><ISOAbbreviation>J Ment Health</ISOAbbreviation></Journal><ArticleTitle>Evidence and implications for early intervention in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>113-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/09638230903469111</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To review the evidence that supports early intervention in the treatment of bipolar disorder.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a pleomorphic condition, with varying manifestations that are determined by a number of complex factors including the "stage" of illness. It is consequently a notoriously difficult illness to diagnose and as a corollary is associated with lengthy delays in recognition and the initiation of suitable treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was conducted using MEDLINE augmented by a manual search.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Emerging neuroimaging data suggests that, in contrast to schizophrenia, where at the time of a first-episode of illness there is already discernible volume loss, in bipolar disorder, gross brain structure is relatively preserved, and it is only with recurrences that there is a sequential, but marked loss of brain volume. Recent evidence suggests that both pharmacotherapy and psychotherapy are more effective if instituted early in the course of bipolar disorder, and that with multiple episodes and disease progression there is a noticeable decline in treatment response.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Such data supports the notion of clinical staging, and the tailored implementation of treatments according to the stage of illness. The progressive nature of bipolar disorder further supports the concept that the first episode is a period that requires energetic broad-based treatment, with the hope that this could alter the temporal trajectory of the illness. It also raises hope that prompt treatment may be neuroprotective and that this perhaps attenuates or even prevents the neurostructural and neurocognitive changes seen to emerge with chronicity. This highlights the need for early identification at a population level and the necessity of implementing treatments and services at a stage of the illness where prognosis is optimal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Biomedical Sciences, University of Melbourne, Parkville, Australia. mikebe@barwonhealth.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallam</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hasty</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Macneil</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yucel</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pantelis</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Seetal</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Ment Health</MedlineTA><NlmUniqueID>9212352</NlmUniqueID><ISSNLinking>0963-8237</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="N">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>105</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20433320</ArticleId><ArticleId IdType="doi">10.3109/09638230903469111</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15482871</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0277-9536</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Social science &amp; medicine (1982)</Title><ISOAbbreviation>Soc Sci Med</ISOAbbreviation></Journal><ArticleTitle>Implications of genetic risk information in families with a high density of bipolar disorder: an exploratory study.</ArticleTitle><Pagination><MedlinePgn>109-18</MedlinePgn></Pagination><Abstract><AbstractText>While major susceptibility genes for bipolar disorder are yet to be identified, the opportunity exists to systematically ascertain the important issues and societal implications of genetic risk determination for bipolar disorder prior to these technological advances becoming widely available. This study explores, in a sample of families with a high density of bipolar disorder: (i) attitudes to predictive genetic and prenatal testing, using different risk frames; (ii) attributions for bipolar disorder, in particular the degree to which a genetic model is endorsed; and (iii) the impact of these attributions on the perceived stigma of bipolar disorder. A qualitative methodology was selected as most appropriate as no previous research has examined this issue. Participants were ascertained through a molecular genetics study of bipolar disorder. In-depth interviews were conducted with 21 members of families with a high density of bipolar disorder. Most participants reported being interested in genetic testing if it gave a definitive answer, while expressed interest in testing was lower if it gave a probable answer only. Almost all stressed that a genetic susceptibility and environmental factors interacted. Most participants felt that a genetic explanation was likely to decrease the stigma associated with bipolar disorder as it shifted the locus of control and responsibility away from the individual towards the role of heredity. Findings indicate that expressed interest in genetic testing depends on the certainty imparted by the test. Results suggest that families with bipolar disorder are likely to benefit psychologically from information about the genetic basis of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meiser</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Sydney NSW 2031, Australia. b.meiser@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>McGirr</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Van Herten</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Soc Sci Med</MedlineTA><NlmUniqueID>8303205</NlmUniqueID><ISSNLinking>0277-9536</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15482871</ArticleId><ArticleId IdType="pii">S0277953604001960</ArticleId><ArticleId IdType="doi">10.1016/j.socscimed.2004.04.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">27307450</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-960X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Evidence-based mental health</Title><ISOAbbreviation>Evid Based Ment Health</ISOAbbreviation></Journal><ArticleTitle>Screening for bipolar disorder: lessons not yet learned.</ArticleTitle><Pagination><MedlinePgn>e16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/eb-2016-102374</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Evid Based Ment Health</MedlineTA><NlmUniqueID>100883413</NlmUniqueID><ISSNLinking>1362-0347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Affect Disord. 2015 Dec 1;188:97-100</RefSource><PMID Version="1">26344754</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27307450</ArticleId><ArticleId IdType="pii">eb-2016-102374</ArticleId><ArticleId IdType="doi">10.1136/eb-2016-102374</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18644800</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3502</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><MedlineDate>2008 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Alcohol and alcoholism (Oxford, Oxfordshire)</Title><ISOAbbreviation>Alcohol Alcohol</ISOAbbreviation></Journal><ArticleTitle>Circadian phenotype in patients with the co-morbid alcohol use and bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>564-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/alcalc/agn057</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Alcohol misuse is associated with bipolar disorder. Abnormalities in the circadian clockwork play a role in the pathogenesis of bipolar disorder. Alcohol intake is likely to affect the circadian phenotype. We aimed at analysing the behavioural trait of the preference to morning or evening hours for the daily activities in bipolar disorder patients with or without the co-morbid alcohol use.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our nationwide sample of families included patients with bipolar disorder born during 1940-1969 having at least one hospitalization due to bipolar disorder during 1969-1991 and their first-degree relatives. All the 148 participants were interviewed using the Structured Clinical Interview for DSM-IV Axis I Disorders and assessed using the Morningness-Eveningness Questionnaire whose factor matrix applying for the maximum likelihood principle was calculated for the first time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with the co-morbid alcohol use disorder were more of the morning type as compared with patients with bipolar disorder only.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Co-morbid patients preferred more the morning hours for their daily activities, indicative of alcohol consumption having an effect on the circadian clock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hätönen</LastName><ForeName>Taina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 166, FI-00300 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsblom</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kieseppä</LastName><ForeName>Tuula</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lönnqvist</LastName><ForeName>Jouko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Partonen</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alcohol Alcohol</MedlineTA><NlmUniqueID>8310684</NlmUniqueID><ISSNLinking>0735-0414</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18644800</ArticleId><ArticleId IdType="pii">agn057</ArticleId><ArticleId IdType="doi">10.1093/alcalc/agn057</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>